

ENGLISH TRANSLATION OF THE ANNUAL GENERAL MEETING CONVENING BROCHURE

Annual General Meeting of DBV Technologies

June 3, 2026 at 10:00 a.m CEST

French société anonyme with share capital of EUR 29,604,244.70

Registered office: 107, avenue de la République – 92320 Châtillon

441 772 522 R.C.S. Nanterre

(the "Company")

Please note that because the Company is a French company, the Annual General Meeting convening Brochure has been translated from French. In the case of any discrepancy between this version and the French version, the French version will prevail.

SUMMARY

1.	LETTER FROM THE CHAIRMAN OF THE BOARD OF DIRECTORS TO THE SHAREHOLDERS	P.2
2.	AGENDA	P.4
3.	TEXT OF THE DRAFT RESOLUTIONS	P.7
4.	REPORT OF THE BOARD OF DIRECTORS ON THE RESOLUTIONS SUBMITTED TO THE ANNUAL GENERAL MEETING	P.46
5.	PROCEDURES FOR PARTICIPATING IN THE ANNUAL GENERAL MEETING	P.72
6.	DOCUMENTS AND INFORMATION RELATING TO THE ANNUAL GENERAL MEETING	P.77
7.	CHANGES IN THE TERMS AND CONDITIONS GOVERNING THE MEETING NOTICE FOR REGISTERED SHAREHOLDERS AS FROM JULY 1 st , 2026	P.78

1. LETTER FROM THE CHAIRMAN OF THE BOARD OF DIRECTORS TO THE SHAREHOLDERS

Dear Fellow DBV Shareholders,

Each year, I begin my letter to you with the reminder that DBV was founded upon the belief that children living with food allergies, their families, and the clinicians who treat them need, and deserve, treatment options. That belief remains the core tenet of DBV today – it guides our corporate strategy as the Company progresses to commercialization with disciplined execution.

In recapping what has been a defining year for DBV, I must begin with the positive topline results from our Phase 3 VITESSE trial evaluating the VIASKIN[®] Peanut Patch in children aged 4 to 7 years. This result represents a milestone that the Company has worked towards over several years with passion. The VITESSE trial was designed with rigor and powered appropriately to support a successful outcome, reflecting the discipline of our development strategy and the careful execution of all those involved. The achievement of this milestone has provided the foundation required to advance the VIASKIN[®] Peanut Patch toward potential commercialization. We are on track to submit the Biologics License Application in the United States in the first half of this year.

In parallel, the Company made significant progress in the toddler population with the advancement of the COMFORT Toddlers supplemental safety trial of the VIASKIN[®] Peanut Patch in children aged 1 to 3 years. Through extensive and constructive dialogue with the U.S. Food and Drug Administration, the Company secured alignment on a path forward for this program and was able to have the first patient screened less than 4 months later. Notably, the eagerness of investigators and clinical sites to participate has been encouraging, and the interest we've seen from caregivers reinforces the unmet need for proactive treatment options in this patient population. The execution of the study, including the efficient management of rolling site activations, further demonstrates the Company's operational capabilities and the discipline of its teams in advancing complex clinical programs.

Specifically, I'd like to highlight THRIVE. This first-of-its-kind study in infants aged 6 through 12 months, is designed to evaluate the VIASKIN[®] Peanut Patch to achieve adlib consumption or the ability to eat peanut freely. This first-of-its-kind study is an example of the Company's continued commitment to the food allergy community and its pursuit to provide treatment options that have the potential to meaningfully change the trajectory and reduce the life-long burden of food allergy.

This commitment to advancing care is not only the right thing to do, it is increasingly aligned with the broader public health and regulatory environment. In February 2026, the U.S. Food and Drug Administration convened an expert panel on food allergies, bringing together scientific, clinical, and patient advocacy voices for a robust academic discussion on the current and future state of the field. The outcome highlighted the need for continued innovation and a greater emphasis on earlier intervention. It's encouraging to hear these conversations further validate VIASKIN as a platform technology and the VIASKIN[®] Peanut Patch's potential as a blockbuster product, once approved.

At the same time, the Company has continued to benefit from close and constructive engagement with the leading scientific, medical, and patient advocacy communities dedicated to advancing the understanding and management of food allergy. Through longstanding relationships with professional

societies and advocacy organizations, DBV Technologies has remained an active participant in the ever-evolving dialogue shaping clinical practice and patient experience. The team has started to feature the robust results from VITESSE at recent medical conferences. Physicians and patient advocacy groups have received these results well and remain enthusiastic about the potential for our science to transform into an approved treatment option for patients.

DBV is still a clinical-stage biopharmaceutical company and as such may need additional funding to support its growth. Execution of the Company's financing strategy is an important highlight of the past year. Through disciplined planning, strong investor engagement, and the ability of the leadership team to operate effectively under pressure, the Company raised \$386.2 million in capital between March 2025 and January 2026. As disclosed in the Company's Q1 2026 press release, this has provided the necessary funding to support its operations into the second quarter of 2027, including the potential US launch of the VIASKIN[®] Peanut Patch. The alignment between the Company and its investors, both new and old, on the near-term path to potential commercialization and the broader vision for the VIASKIN platform cannot be understated.

Looking ahead, DBV Technologies is poised to become a commercial company: it enters this period of growth and change supported by a strengthened financial position, expanded organizational capabilities, and a clear focus on disciplined execution. With conviction, DBV remains a champion of clinical science and to addressing the urgent unmet medical need that exists for food allergic patients and their families. The work we do matters and has impact. DBV is committed to bringing the VIASKIN[®] Peanut Patch to potential approval in the United States. As I have stated before, I state again: our confidence in the significant therapeutic and commercial potential of the VIASKIN[®] Peanut Patch, and in the broader VIASKIN technology platform, is unwavering.

Sincerely,

Michel de Rosen

Chairman of the Board of Directors

2. AGENDA

Within the authority of the ordinary shareholders' meeting:

1. Approval of the annual financial statements for the year ended December 31, 2025
2. Approval of the consolidated financial statements for the year ended December 31, 2025
3. Allocation of income for the year ended December 31, 2025
4. Allocation of the accumulated deficit to the "Additional paid-in capital"
5. Statutory auditors' special report on regulated agreements
6. Renewal of the term of office of KPMG, as statutory auditor
7. Ratification of the provisional appointment of Ms. Philina Lee, as director
8. Renewal of Mr. Michael J. Goller, as director
9. Renewal of Mr. Daniel Tassé, as director
10. Renewal of Ms. Maïlys Ferrère, as director
11. Approval of the information set out in section I of Article L.22-10-9 of the French Commercial Code on the compensation of corporate officers for the year ended December 31, 2025
12. Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Mr. Michel de Rosen, Chairman of the Board of Directors
13. Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Mr. Daniel Tassé, Chief Executive Officer
14. Advisory opinion on the compensation of named executive officers other than the Chief Executive Officer
15. Increase of the total remuneration (annual budget) allocated to Directors
16. Approval of the compensation policy for the Chairman of the Board of Directors for the year ending December 31, 2026
17. Approval of the compensation policy for the Directors for the year ending December 31, 2026
18. Approval of the compensation policy for the Chief Executive Officer and Deputy Chief Executive Officer for the year ending December 31, 2026
19. Authorization to be granted to the Board of Directors to buy back company shares on the Company's behalf pursuant to Article L.22-10-62 of the French Commercial Code

Within the authority of the extraordinary shareholders' meeting:

20. Delegation to be granted to the Board of Directors to reduce the share capital by cancellation of shares pursuant to Article L.22-10-62 of the French Commercial Code

21. Delegation of authority to be granted to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities and/or securities giving access to ordinary shares with preferential subscription rights
22. Delegation of authority to be granted to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities, and/or securities giving access to equity securities to be issued, without preferential subscription rights by means of a public offer excluding the offers set out in paragraph 1 of Article L.411-2 of the French Monetary and Financial Code, and/or as consideration for securities in the context of a public exchange offer
23. Delegation of authority to be granted to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities, and/or securities giving access to equity securities to be issued, without preferential subscription rights by means of a public offer referred to in paragraph 1 of Article L.411-2 of the French Monetary and Financial Code
24. Delegation of powers to be granted to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities and/or securities giving access to ordinary shares, without preferential subscription rights in favor of one or more persons specifically designated by the Board of Directors
25. Delegation of authority to be granted to the Board of Directors to issue ordinary shares, giving, as the case may be, access to ordinary shares or the allocation of debt securities (of the Company or a group company) and/or securities giving access to ordinary shares (of the Company or a group company), without preferential subscription rights in favor of a category of persons satisfying determined characteristics
26. Delegation of authority to be granted to the Board of Directors to decide on the issue of ordinary shares to be issued immediately or in the future by the Company, without preferential subscription rights in favor of a category of persons satisfying determined characteristics within the framework of an equity financing agreement on the United States stock market known as “At-The-Market” or “ATM Program”
27. Delegation of authority to be granted to the Board of Directors to increase the number of securities to be issued in the event of a capital increase with or without preferential subscription rights, in the event of excess demand
28. Delegation to be granted to the Board of Directors to increase the share capital by issuance of ordinary shares and/or securities giving access to the share capital within the limits set by the applicable legal and regulatory provisions on the date of the capital increase in consideration for contributions in kind of securities or securities giving access to the share capital
29. Delegation of authority to be granted to the Board of Directors to decide on any merger-absorption, spin-off or partial contribution of assets
30. Delegation of authority to be granted to the Board of Directors to issue ordinary shares giving, as the case may be, access to ordinary shares or to the allocation of debt securities (of the Company or of a group company), and/or securities giving access to ordinary shares (of the Company or of a group company), in the context of a merger, spin-off or partial

- contribution of assets decided by the Board of Directors pursuant to the delegation referred to in the twenty-ninth resolution
31. Overall limit on the maximum authorized amounts set under the resolutions twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-eighth and thirtieth
 32. Delegation of authority to be granted to the Board of Directors to increase the capital by means of the incorporation of reserves, profits and/or premiums
 33. Delegation of authority to be granted to the Board of Directors to increase the capital by the issue of ordinary shares and/or securities giving access to the share capital, without preferential subscription rights in favor of the members of a company savings plan pursuant to Articles L.3332-18 and seq. of the French Labor Code
 34. Delegation of authority to be granted to the Board of Directors to issue warrants (BSA), subscription and/or acquisition of new and/or existing warrants (BSAANE) and/or subscription and/or acquisition of new and/or existing redeemable warrants (BSAAR) without preferential subscription rights in favor of a category of persons
 35. Authorization to be granted to the Board of Directors to allocate for free existing and/or to be issued shares to employees and/or certain corporate officers of the Company or related companies or economic interest groups
 36. Authorization to be granted to the Board of Directors to grant stock options to employees and/or certain officers of the Company or related companies or economic interest groups
 37. Overall limit on the maximum authorized amounts set under the resolutions thirty-fifth and thirty-sixth
 38. Ratification of the amendment to Article 18 and Article 21 of the Company's bylaws
 39. Amendment to Article 15 of the Company's bylaws to set the age limit for the Chief Executive Officer at 70 years

Within the authority of the ordinary shareholders' meeting:

40. Powers to complete formalities

3. TEXT OF THE DRAFT RESOLUTIONS

1. First Resolution (*Approval of the annual financial statements for the year ended December 31, 2025*).

- The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings and having reviewed the Board of Directors' report and the Statutory Auditors' special report on the financial year ended December 31, 2025, approves these annual financial statements as they were presented, which record a loss of 123,018,389.41 euros, as well as the transactions reflected in these accounts and summarized in these reports.

2. Second Resolution (*Approval of the consolidated financial statements for the year ended December 31, 2025*). - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings, and having reviewed the Board of Directors' report and the Statutory Auditors' special report on the consolidated financial statements as of December 31, 2025, approves these financial statements as they were presented, which record a loss (group share) of 146,946,904.70 dollars (US GAAP) & 147,156,369.31 dollars (IFRS), as well as the transactions reflected in these accounts and summarized in these reports.

3. Third Resolution (*Allocation of income for the year ended December 31, 2025*).

- The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings, and having reviewed the Board of Directors' report, decides to fully allocate the whole of the net loss for the financial year ended December 31, 2025, totaling of 123,018,389.41 euros, to the "Accumulated deficit" line, which would result in a negative balance of 190,148,327.46 euros and notes, pursuant to Article 243 bis of the French General Tax Code, that no distribution of dividends or income has occurred in the past three financial years.

4. Fourth Resolution (*Allocation of the accumulated deficit to the "Additional paid-in capital"*).

- The General Meeting, acting in accordance with the quorum and majority requirements for ordinary meetings, and having considered the report of the Board of Directors:

- notes that the retained earnings account shows a debit balance of 190,148,327.46 euros after allocation of the net loss of the financial year ended December 31, 2025,
- decides to charge 190,148,327.46 euros to the additional paid-in capital account, which, before this charge, amounts to 312,354,226.86 euros, and
- notes that the additional paid-in capital account will amount, after this charge, to 122,205,899.40 euros.

5. Fifth Resolution (*Statutory auditors' special report on regulated agreements*). – The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings and having reviewed the report of the Board of Directors and the Statutory Auditors' special report on related-party agreements presented to it, notes the terms of said report and approves it.

6. Sixth Resolution (*Renewal of the term of office of KPMG, as statutory auditor*) - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings and having reviewed the report of the Board of Directors, acknowledges that the term of office of KPMG, statutory auditor, expires at the end of this General Meeting and decides to renew the said term of office for a six-year term, to expire at the end of the General Meeting to be held in 2032 to approve the financial statements for the previous financial year.

7. Seventh Resolution (*Ratification of the provisional appointment of Ms. Philina Lee, as director*) - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings, ratifies the provisional appointment by the Board of Directors at its meeting on October 30, 2025, of Ms. Philina Lee as a Director, to replace Daniel Soland, who has resigned, for the remaining term of office of her predecessor and therefore expiring at the ordinary General Meeting to be held in 2028 in order to approve the financial statements for the financial year ended on December 31, 2027.

8. Eighth Resolution (*Renewal of Mr. Michael J. Goller, as director*). - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings and having reviewed the report of the Board of Directors, decides to renew the term as Director of Michael J. Goller, for a period of three years, to expire at the end of the General Meeting to be held in 2029 to approve the financial statements for the previous financial year.

9. Ninth Resolution (*Renewal of Mr. Daniel Tassé, as director*). - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings, and having reviewed the Board of Directors' report, decides to renew the term as Director of Daniel Tassé, for a period of three years, to expire at the end of the General Meeting to be held in 2029 to approve the financial statements for the previous financial year.

10. Tenth Resolution (*Renewal of Ms. Mailys Ferrère, as director*). - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings, and having reviewed the Board of Directors' report, decides to renew the term as Director of Mailys Ferrère, for a period of three years, to expire at the end of the General Meeting to be held in 2029 to approve the financial statements for the previous financial year.

11. Eleventh Resolution (*Approval of the information set out in section I of Article L.22-10-9 of the French Commercial Code on the compensation of corporate officers for the year 2025*). - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings, having reviewed the Board of Directors' report and the report on corporate governance referred to in Article L.225-37 of the Commercial Code, and acting pursuant to Article L.22-10-34 of the French Commercial Code, approves the information set out in section I of Article L.22-10-9 of the French Commercial Code, as detailed in the corporate governance report, contained in paragraph 3.4 of the Universal Registration Document 2025.

12. Twelfth Resolution (*Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Mr. Michel de Rosen, Chairman of the Board of Directors*). - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings, having reviewed the

report of the Board of Directors and acting pursuant to Article L. 22-10-34 II of the French Commercial Code, approves the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025 to Michel de Rosen, Chairman of the Board of Directors, as detailed in the corporate governance report, contained in paragraph 3.4 of the Universal Registration Document 2025.

13. Thirteenth Resolution (*Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Mr. Daniel Tassé, Chief Executive Officer*). - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings, having reviewed the report of the Board of Directors and acting pursuant to Article L. 22-10-34 II of the French Commercial Code, approves the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025 to Daniel Tassé, Chief Executive Officer, as detailed in the corporate governance report, contained in paragraph 3.4 of the Universal Registration Document 2025.

14. Fourteenth Resolution (*Advisory opinion on the compensation of named executive officers other than the Chief Executive Officer*) - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings, having reviewed the report of the Board of Directors, issues, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act - Section 951, a favorable opinion on the compensation policy applicable to Kevin Trapp, Virginie Boucinha and Pharis Mohideen, named executive officers and members of the Company's executive committee for the year ending December 31, 2026, as detailed in the corporate governance report, contained in paragraph 3.4 of the Universal Registration Document 2025.

15. Fifteenth Resolution (*Increase of the total remuneration (annual budget) allocated to Directors*). - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings, decides to increase from €900,000 to €1,150,000 the total annual amount available to the directors for the fulfilment of their duties for the 2026 financial year and for each subsequent financial year, until a new decision is adopted by the General Meeting of Shareholders.

16. Sixteenth Resolution (*Approval of the compensation policy for the Chairman of the Board of Directors for the year 2026*) - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings, having reviewed the report of the Board of Directors and the report on corporate governance referred to in Article L.225-37 of the Commercial Code, describing the elements of the compensation policy for corporate officers, and acting pursuant to Article L. 22-10-8 II of the French Commercial Code, approves the compensation policy for the Chairman of the Board of Directors for the year ending December 31, 2026, as detailed in the corporate governance report, contained in paragraph 3.4 of the Universal Registration Document 2025.

17. Seventeenth Resolution (*Approval of the compensation policy for the Directors for the year ending December 31, 2026*). - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings, having reviewed the report of the Board of Directors and the report on corporate governance referred to in Article L.225-37 of the Commercial Code, describing the elements of the compensation policy for corporate officers, and acting pursuant to Article L. 22-10-8 II of the French Commercial Code, approves the compensation policy for the

Directors for the year ending December 31, 2026, as detailed in the corporate governance report, contained in paragraph 3.4 of the Universal Registration Document 2025.

18. Eighteenth Resolution (*Approval of the compensation policy for the Chief Executive Officer and Deputy Chief Executive Officer for the year ending December 31, 2026*). - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings, having reviewed the report of the Board of Directors and the report on corporate governance referred to in Article L.225-37 of the Commercial Code, describing the elements of the compensation policy for corporate officers, and acting pursuant to Article L. 22-10-8 II of the French Commercial Code, approves the compensation policy for the Chief Executive Officer and Deputy Chief Executive Officer for the year ending December 31, 2026, as detailed in the corporate governance report, contained in paragraph 3.4 of the Universal Registration Document 2025.

19. Nineteenth Resolution (*Authorization to be granted to the Board of Directors to buy back company shares on the Company's behalf pursuant to Article L.22-10-62 of the French Commercial Code*) - The General Meeting, acting in accordance with the quorum and majority requirements for ordinary shareholders' meetings, having reviewed the report of the Board of Directors:

- authorizes the Board of Directors, with the option of sub-delegation under the conditions provided for by law, for a period of eighteen (18) months from the date of this General Meeting, in accordance with the provisions of Articles L.225-210 and seq. and L.22-10-62 and seq. of the French Commercial Code, Articles 241-1 to 241-5 of the General Regulations of the *Autorité des Marchés Financiers* (AMF) and Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014 on market abuse as amended, to purchase or arrange for the purchase of shares in the Company,
- decides that acquisition, sale, exchange or transfer of these shares may be executed by any means, including through the purchase of share blocks, at the time deemed appropriate, excluding periods of public offers on the Company's share capital, and by any means, on one or more occasions, notably on the market or over-the-counter, including by acquisition or sale of blocks or public offers, using option or derivative mechanisms, under the conditions provided for by the market authorities and in compliance with applicable regulations,
- decides that the authorization may be used to:
 - support the secondary market or the liquidity of the Company's shares through a liquidity agreement with an investment service provider, acting independently, in accordance with the standard practice accepted by the AMF,
 - implement all stock option plans (or similar plans), all free share allocation plans (or similar plans), all employee savings plans (or similar plans) or all other allocations of shares to employees and managers of the Company or its affiliates, as well as to carry out all hedging operations relating to these transactions under the conditions and in accordance with the provisions of the applicable laws and regulations,
 - remit shares on the exercise of rights attached to securities giving access to the capital, and to carry out all hedging operations relating to these transactions under the conditions and in accordance with the provisions of the applicable laws and regulations,

- purchase shares to be held and subsequently exchanged or paid for in connection with any external growth, merger, demerger or contribution transactions,
- cancel all or part of the shares acquired, or
- more generally, to operate for any purpose that may be authorized by law or any market practice that may be permitted by the market authorities, it being specified that, in such a case, the Company would inform its shareholders by way of a press release,
- decides to set the maximum purchase price (excluding charges) at 25 euros per share (or the equivalent of this amount on the same date in any other currency), with an overall ceiling of 370,053,000 euros, it being specified that this maximum purchase price will be subject to any necessary adjustments in order to take account of capital transactions (in particular in the event of the incorporation of reserves and the free allocation of shares, splits or consolidation of shares) which would occur during the period of validity of this authorization,
- resolves that the maximum number of shares that may be purchased under this resolution may not, at any time, exceed five percent (5%) of the total number of shares comprising the share capital at the date of purchase, this percentage being applied to a share capital figure adjusted to take account of transactions affecting it subsequent to this General Meeting, it being specified that (i) when the shares are purchased in order to promote the liquidity of the Company's shares, the number of shares taken into account for the calculation of this limit will correspond to the number of shares purchased less the number of shares resold during the term of the authorization, and (ii) when they are purchased with a view to their retention and subsequent remittance in payment or exchange in the context of a merger, demerger or contribution, the number of shares purchased may not exceed five percent (5%) of the total number of shares,
- grants full powers to the Board of Directors, with the option of sub-delegation under the conditions provided for by law, to implement the present authorization, in particular to judge the appropriateness of launching a share buyback program and to determine the terms and conditions thereof, to place all stock market orders, and to sign all deeds of sale or transfer, enter into any agreements, liquidity contracts or option contracts, make any declarations to the *Autorité des Marchés Financiers* and any other body, and carry out any necessary formalities, in particular to allocate or reallocate the shares acquired for the various formalities, and, in general, to do all that is necessary,
- notes that the Board of Directors must inform the ordinary Shareholders' Meeting, in accordance with the law, of transactions carried out under this authorization,
- terminates, with immediate effect, the unused portion of the authorization granted by the General Meeting of June 11, 2025 in its nineteenth resolution to purchase shares of the Company.

Extraordinary resolutions

20. Twentieth Resolution (*Delegation to be granted to the Board of Directors to reduce the share capital by cancellation of shares pursuant to Article L. 22-10-62 of the French Commercial Code*). - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary

shareholders' meetings and having reviewed the Board of Directors' report and the Statutory Auditors' report:

- authorizes the Board of Directors, in accordance with Article L. 22-10-62 and seq. of the French Commercial Code, for a period of eighteen (18) months from the date of this meeting, to cancel, on one or more occasions, within the maximum limit of ten percent (10%) of the amount of the share capital per period of twenty-four (24) months, all or part of the shares acquired by the Company under the share repurchase program authorized by the nineteenth resolution submitted to this General Meeting or under share repurchase programs authorized previously or subsequently, and to reduce the share capital accordingly, in the proportions and at the times it deems appropriate, it being specified that this limit applies to the amount of the share capital on the date of the reduction,
- decides that any excess of the purchase price of the shares over their nominal value shall be charged to the share, merger or contribution premiums or to any available reserve premium, including the legal reserve, subject to this not falling below ten percent (10%) of the Company's share capital after completion of the capital reduction,
- grants full powers to the Board of Directors, with the option to sub-delegate under the conditions provided for by law, to proceed with the capital reduction resulting from the cancellation of ordinary shares, to determine the final amount of the capital reduction, to set the terms and conditions thereof and to record the completion thereof and to carry out all acts, formalities or declarations with a view to making final the capital reductions that could be carried out under this authorization and for the purpose of amending the Company's bylaws accordingly,
- terminates, with immediate effect, the unused portion of the authority granted by the General Meeting of June 11, 2025 in its twentieth resolution to cancel shares of the Company.

21. Twenty-first Resolution (*Delegation of authority to be granted to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities and/or securities giving access to ordinary shares with preferential subscription rights*).

- The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings and having reviewed the Board of Directors' report and the Statutory Auditors' special report and pursuant to the French Commercial Code, in particular Articles L. 225-129, L. 225-129-2, L. 225-132 to L. 225-134, L. 228-91 and seq. and L. 22-10-49:

- 1) delegates to the Board of Directors, with the option of sub-delegation under the conditions provided for by law, its authority to issue, on one or more occasions, in the proportions and at the times of its choosing, on the French and/or international market either in euros or in any other currency or in any other currency units established by reference to several currencies, with or without premium, free of charge or for a price:
 - ordinary shares, and/or
 - securities which are equity securities giving access to other equity securities or to the allocation of debt securities, and/or
 - securities, including debt securities, giving access to equity securities to be issued, it being

specified that, pursuant to Article L. 228-93 of the French Commercial Code, the securities to be issued may give access to equity securities to be issued by the Company and/or any company that directly or indirectly owns over than half of its share capital or of which it directly or indirectly owns over than half of the share capital;

the subscription for which may be settled either in cash or by offsetting receivables;

- 2) sets the term of validity of this authorization at twenty-six (26) months from the date of this General Meeting;
- 3) decides to fix the limits to the amounts of authorized issues if the Board of Directors should use this delegation of competence:
 - the maximum nominal amount of the share capital increases that may be performed, immediately or in the future, resulting from all of the issues carried out under this delegation may not exceed 29,604,244 euros or the equivalent in any other currency, or in any other currency units established by reference to several currencies; this cap is independent from all the caps provided for in the other resolutions of this Meeting;
 - added to this cap will be, as the case may be, the nominal value of the ordinary shares to be issued to preserve, in accordance with applicable law and, as the case may be, contractual provisions that provide for other cases of adjustments, the rights of the holders of securities giving access to the Company's share capital;
 - the securities giving access to ordinary shares to be issued immediately or in the future by the Company may notably consist of debt securities or warrants, or be associated with the issue of such securities, or allow their issue as intermediate securities;
- 4) decides to set the following limits on the amounts of debt securities authorized in the event of the issue of securities in the form of debt securities giving immediate or future access to the share capital of the Company or of other companies:
 - the maximum nominal amount of the debt securities that may be issued pursuant to this authorization may not exceed 200,000,000 euros or the equivalent of this amount in any other currency or currency units established by reference to several currencies;
 - this amount will be increased, as the case may be, by any redemption premium above par and is independent of the amount of debt securities whose issuance could result from the use of other resolutions submitted to this Meeting and of debt securities whose issuance would be decided or authorized by the Board of Directors in accordance with Articles L.228-36-A, L.228-40, L.228-92 paragraph 3, L.228-93 paragraph 6 and L.228-94 paragraph 3 of the French Commercial Code;
- 5) if the Board of Directors decides to use this delegation of authority:
 - decides that the issue(s) of ordinary shares or securities giving access to the share capital shall be preferentially reserved to shareholders, who may subscribe them on an irrevocable basis, in proportion to the number of shares they own,
 - decides that the Board of Directors may institute a right for shareholders to subscribe for ordinary shares and securities issued pursuant to this resolution on a reducible basis, which

- shall be exercised in proportion to the subscription rights they hold within the limit of their requests,
- acknowledges that this delegation of authority automatically entails, in favor of the holders of securities giving access or likely to give access to equity securities to be issued by the Company, the waiver by shareholders of their preferential subscription rights to subscribe for the shares to which these securities will give immediate or future entitlement,
 - decides, in accordance with Article L.225-134 of the French Commercial Code, that if subscriptions on an irreducible basis, and as the case may be, on a reducible basis, have not absorbed the entire issue decided by virtue of the present delegation, the Board of Directors may use, under the conditions provided for by law and in the order it shall determine, the following options:
 - to limit the amount of the issue to the amount of subscriptions, it being specified that in the event of an issue of ordinary shares or securities whose primary security is a share, the amount of subscriptions must reach at least three-quarters of the issue decided upon for this limitation to be possible,
 - freely allocate all or part of the unsubscribed securities,
 - offer to the public all or part of the unsubscribed securities,
 - decides that the issuance of Company's warrants may be performed by subscription offer as well as by allocation to the owners of the existing shares, it being specified that the Board of Directors shall have the right to decide that the allotment rights forming fractions shall not be negotiable and the corresponding securities will be sold in accordance with the applicable legal and regulatory provisions;
- 6) decides that the Board of Directors may not, except with the prior authorization of the General Meeting, make use of this delegation of authority as from the filing by a third party of a proposed public offer for the Company's securities until the end of the offer period;
- 7) decides that the Board of Directors, within the limits set out above, with option of sub-delegation under the conditions provided for by law, will have full powers to implement this delegation of authority, and in particular to:
- to decide to issue shares and/or securities and to determine their characteristics, in particular the amount of the issue, the issuance price and the amount of the premium that may be requested on issue, the terms and conditions of their subscription and payment and their date of entitlement to dividends, and to determine the dates and terms of issue, the nature, number and characteristics of the shares and/or securities to be created and issued;
 - in the event of the issue of warrants, to determine the number and characteristics of such warrants and to decide, if it deems appropriate, under the terms and conditions it shall determine, that the warrants may be redeemed or repurchased, or that they shall be allocated free of charge to the shareholders in proportion to their rights in the share capital;
 - more generally, to determine the characteristics of all securities and, in particular, the terms and conditions for the allotment of shares, the duration of loans that may be issued

in the form of bonds, whether they are subordinated or not, the currency of issue, the terms of repayment of the principal, with or without premium, the terms and conditions of redemption and, as the case may be, of purchase, exchange or early redemption, the interest rate, whether fixed or variable, and the payment date; the remuneration may include a variable portion calculated by reference to factors relating to the Company's business and results and a deferred payment in the absence of distributable profits; to set the terms and conditions under which the Company will have the option, as the case may be, to purchase or exchange on the stock market, at any time or during specified periods, the securities issued or to be issued immediately or in the future with a view to cancelling them or not, taking into account the legal provisions;

- provide the possibility to suspend the exercise of rights attached to the shares or securities issued, for up to three (3) months, in accordance with legal and regulatory provisions;
 - charge the fees related to the capital increase against the related premiums and deduct from this amount the sums necessary to increase the legal reserve;
 - determine and make all adjustments to take into account the impact of transactions on the Company's share capital or shareholders' equity;
 - record the completion of each capital increase and make the corresponding amendments to the by-laws;
 - generally, enter into any agreement, in particular to ensure the successful completion of the planned issues, take all measures and carry out all formalities necessary for the issue, listing and financial servicing of the securities issued pursuant to this delegation, as well as for the exercise of the rights attached thereto;
- 8) acknowledges that, in the event that the Board of Directors decides to exercise the delegation of authority conferred upon it in this resolution, the Board of Directors will report to the next Ordinary General Meeting, in compliance with the law and the regulations, on the use of the delegation granted under this resolution;
- 9) notes that this delegation renders ineffective, as from the date hereof, any unused portion, as the case may be, of the delegation of authority granted by the General Meeting of June 11, 2025 in its twenty-first resolution.

22. Twenty-second Resolution (*Delegation of authority to be granted to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities, and/or securities giving access to equity securities to be issued, without preferential subscription rights, by means of a public offer excluding the offers set out in paragraph 1 of Article L.411-2 of the French Monetary and Financial Code, and/or as consideration for securities in the context of a public exchange offer*). - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings and having reviewed the Board of Directors' report and the Statutory Auditors' special report and pursuant to the French Commercial Code, in particular Articles L. 225-129-2 and seq., L. 22-10-49, L. 22-10-51, L. 22-10-54 and L.228-91 and seq. of said Code:

- 1) delegates to the Board of Directors, with the option of sub-delegation under the conditions provided for by law, its authority to issue, without preferential subscription rights, on one or

more occasions, in the proportions and at the times of its choosing, on the French and/or international market by means of a public offer excluding the offers set out in section 1 of Article L.411-2 of the French Monetary and Financial Code, in euros, any other currency or in any other currency units established by reference to several currencies, with or without premium, free of charge or for a price:

- ordinary shares and/or
- securities which are equity securities giving access to other equity securities or to the allocation of debt securities, and/or
- securities, including debt securities, giving access to ordinary shares to be issued, it being specified that, pursuant to Article L. 228-93 of the French Commercial Code, the securities to be issued may give access to equity securities to be issued by the Company and/or any company that directly or indirectly owns over than half of its share capital or of which it directly or indirectly owns over than half of the share capital;

the subscription for which may be settled either in cash or by offsetting receivables;

these securities may be issued for the purpose of paying for securities contributed to the Company in a public exchange offer, pursuant to the conditions of Article L. 22-10-54 of the French Commercial Code;

public offerings made pursuant to this resolution, which may be combined, in the context of the same issue or of several issues made simultaneously, with public offerings referred to in 1° of Article L. 411-2 of the French Monetary and Financial Code;

- 2) sets the term of validity of this authorization at twenty-six (26) months from the date of this General Meeting;
- 3) decides to set the following limits on the amounts of the capital increases authorized in the event of use by the Board of Directors of the present delegation of authority:
 - the maximum nominal amount of capital increases that may be performed pursuant to this delegation may not exceed 29,604,244 euros or the equivalent in any other currency, or in any other currency units established by reference to several currencies, it being specified that this maximum amount counts toward the overall limit referred to in the thirty-first resolution of this Meeting;
 - added to this cap will be, as the case may be, the nominal value of the ordinary shares to be issued to preserve, in accordance with applicable laws and, as the case may be, contractual provisions that provide for other cases of adjustments, the rights of the holders of securities giving access to the Company's share capital;
- 4) decides to set the following limits on the amounts of debt securities authorized in the event of the issue of securities in the form of debt securities giving immediate or future access to the share capital of the Company or of other companies:
 - the maximum nominal amount of the debt securities that may be issued pursuant to this delegation may not exceed 200,000,000 euros or the equivalent in any other currency, or

in any other currency units established by reference to several currencies; it being specified that this cap counts toward the overall limit provided for in the thirty-first resolution of this Meeting;

- this amount will be increased, as the case may be, by any redemption premium above par and is independent of the amount of debt securities whose issuance would be decided or authorized by the Board of Directors in accordance with Articles L.228-36-A, L.228-40, L.228-92 paragraph 3, L.228-93 paragraph 6 and L.228-94 paragraph 3 of the French Commercial Code;
- 5) if the Board of Directors uses this delegation of authority
- decides to waive the preferential subscription rights over ordinary shares and securities covered by this resolution, and to delegate to the Board of Directors the option to grant, if necessary, under the conditions provided for in Article L. 22-10-51 of the French Commercial Code, for all or part of an issue, an irreducible and/or reducible priority subscription right in favor of the shareholders;
 - acknowledges that this delegation automatically entails, in favor of the holders of securities giving access to the share capital, the express waiver by the shareholders of their preferential subscription right to subscribe for the shares to which these securities will give immediate or future entitlement;
 - decides, in accordance with Article L. 225-134 of the French Commercial Code, that if subscriptions, including, as the case may be, those of the shareholders, have not absorbed the entire issue, the Board of Directors may use, in the order it shall determine, all or some of the following options:
 - limit the amount of the issue to the amount of subscriptions, it being specified that in the event of an issue of ordinary shares or securities whose primary security is a share, the amount of subscriptions must reach at least three-quarters of the issue decided upon for this limitation to be possible,
 - freely allocate all or part of the unsubscribed securities;
 - decides that the issuance price of the ordinary shares that may be issued under this delegation of authority shall be at least equal to, at the discretion of the Board of Directors or the Chief Executive Officer:
 - either to the last closing price of the Company's shares preceding the setting of the issue price, possibly reduced by a maximum discount of 15%,
 - either to the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris over a period chosen by the Board of Directors or, as the case may be, the Chief Executive Officer, comprising between one and five consecutive trading sessions among the last thirty trading sessions preceding the setting of the issue price, possibly reduced by a maximum discount of 15%,
 - decides that the issue price of the securities giving access to the share capital, as the case may be, issued pursuant to this delegation shall be equal to the amount received immediately by the Company, increased by the amount likely to be received by the

Company upon the exercise, conversion, redemption or exchange of such securities, or, for each share issued as a result of the issuance of these securities, at least equal to the amount mentioned in the preceding paragraph;

- 6) decides, in the event of the issuance of securities intended to remunerate securities contributed in connection with a public exchange offer, pursuant to the conditions of Article L. 22-10-54 of the French Commercial Code, and within the limits set out above, to grant the Board of Directors the power required to draft the list of securities included in the exchange, to set the terms and conditions of the issue, the share-for-share basis, and, as the case may be, the amount of the equalization payment in cash and to determine the terms and conditions of issue;
- 7) decides that the Board of Directors may not, except with the prior authorization of the General Meeting, make use of this delegation of authority as from the filing by a third party of a proposed public offer for the Company's securities until the end of the offer period;
- 8) decides that the Board of Directors, within the limits set out above, with option of sub-delegation under the conditions provided for by law, will have full powers to implement this delegation of authority, and in particular to:
 - to decide to issue shares and/or securities and to determine their characteristics, in particular the amount of the issue, the issuance price and the amount of the premium that may be requested on issue, the terms and conditions of their subscription and payment and their date of entitlement to dividends, and to determine the dates and terms of issue, the nature, number and characteristics of the shares and/or securities to be created and issued;
 - in the event of the issue of warrants, to determine the number and characteristics of such warrants and to decide, if it deems appropriate, under the terms and conditions it shall determine, that the warrants may be redeemed or repurchased, or that they shall be allocated free of charge to the shareholders in proportion to their rights in the share capital;
 - more generally, to determine the characteristics of all securities and, in particular, the terms and conditions for the allotment of shares, the duration of loans that may be issued in the form of bonds, whether they are subordinated or not, the currency of issue, the terms of repayment of the principal, with or without premium, the terms and conditions of redemption and, as the case may be, of purchase, exchange or early redemption, the interest rate, whether fixed or variable, and the date of payment; the remuneration may include a variable portion calculated by reference to factors relating to the Company's business and results and a deferred payment in the absence of distributable profits; to set the terms and conditions under which the Company will have the right, as the case may be, to purchase or exchange on the stock market, at any time or during specific periods, the securities issued or to be issued immediately or in the future with a view to cancelling them or not, taking into account the legal provisions;
 - provide the possibility to suspend the exercise of rights attached to the shares or securities issued, for up to three (3) months, in accordance with legal and regulatory provisions;
 - to charge the fees related to the capital increase against the related premiums and deduct from this amount the sums necessary to increase the legal reserve;
 - to determine and make all adjustments to take into account the impact of transactions on

the Company's share capital or shareholders' equity;

- record the completion of each capital increase and make the corresponding amendments to the by-laws;
 - generally, enter into any agreement, in particular to ensure the successful completion of the planned issues, take all measures and carry out all formalities necessary for the issue, listing and financial servicing of the securities issued pursuant to this delegation, as well as for the exercise of the rights attached thereto;
- 9) acknowledges that, in the event that the Board of Directors decides to use the delegation of authority conferred upon it in this resolution, the Board of Directors will report to the next Ordinary General Meeting, in compliance with the law and the regulations, on the use of the delegation granted under this resolution;
- 10) notes that this delegation renders ineffective, as from the date hereof, any unused portion, as the case may be, of the delegation of authority granted by the General Meeting of June 11, 2025 in its twenty-second resolution.

23. Twenty-third Resolution (*Delegation of authority to be granted to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities, and/or securities giving access to equity securities to be issued, without preferential subscription rights, by means of a public offer referred to in paragraph 1 of Article L. 411-2 of the French Monetary and Financial Code*). - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings, having reviewed the Board of Directors' report and the Statutory Auditors' special report and acting in accordance with Articles L. 225-129-2 and seq. of the French Commercial Code, L. 22-10-49 and L. 228-91 and seq. of said Code and Article L. 411-2 1° of the French Monetary and Financial Code:

- 1) delegates to the Board of Directors, with the option of sub-delegation under the conditions provided for by law, its authority to issue, without preferential subscription rights, on one or more occasions, in the proportions and at the times of its choosing, on the French and/or international market, by means of a public offer referred to in paragraph 1 of Article L.411-2 of the French Monetary and Financial Code, in euros, or in any other currency or in any other currency units established by reference to several currencies, with or without premium, free of charge or for a price:
- ordinary shares, and/or
 - securities which are equity securities giving access to other equity securities or the allocation of debt securities, and/or
 - securities, including debt securities, giving access to equity securities to be issued, it being specified that, pursuant to Article L. 228-93 of the French Commercial Code, the securities to be issued may give access to equity securities to be issued by the Company and/or any company that directly or indirectly owns over than half of its share capital or of which it directly or indirectly owns over than half of the share capital;

the subscription for which may be settled either in cash or by offsetting receivables;

- 2) sets the term of validity of this authorization at twenty-six (26) months from the date of this General Meeting;
- 3) decides to set the following limits on the amounts of the capital increases authorized in the event of use by the Board of Directors of the present delegation of authority:
 - the maximum nominal amount of capital increases that may be performed under this delegation may not exceed 29,604,244 euros or the equivalent in any other currency, or in any other currency units established by reference to several currencies, it being specified that, in any event, the nominal amount of the capital increases performed pursuant to this resolution may not exceed the limit set by applicable laws and regulations at the time of implementation of this delegation (on an indicative basis, currently 30% of the share capital per year in accordance with the provisions of Article L.225-136 of the French Commercial Code) and counts toward the overall limit provided for in the thirty-first resolution of this Meeting;
 - added to this cap will be, as the case may be, the nominal value of the ordinary shares to be issued to preserve, in accordance with applicable law and, as the case may be, contractual provisions that provide for other cases of adjustments, the rights of the holders of securities giving access to the Company's share capital;
- 4) decides to set the following limits on the amounts of debt securities authorized in the event of the issue of securities in the form of debt securities giving immediate or future access to the share capital of the Company or of other companies:
 - the maximum nominal amount of the debt securities that may be issued pursuant to this authorization may not exceed 200,000,000 euros or the equivalent in any other currency, or currency units established by reference to several currencies; it being specified that this cap will be deducted from the overall limit referred to in the thirty-first resolution of this Meeting;
 - this amount will be increased, as the case may be, by any redemption premium above par and is independent of the amount of debt securities whose issuance would be decided or authorized by the Board of Directors in accordance with Articles L.228-36-A, L.228-40, L.228-92 paragraph 3, L.228-93 paragraph 6 and L.228-94 paragraph 3 of the French Commercial Code;
- 5) if the Board of Directors decides to use this delegation of authority:
 - decides to waive shareholders' preferential subscription rights to ordinary shares and to securities covered by this resolution;
 - acknowledges that this delegation automatically entails, in favor of the holders of securities giving access to the share capital, the express waiver by the shareholders of their preferential subscription right to subscribe for the shares to which these securities will give immediate or future entitlement;
 - decides, in accordance with Article L.225-134 of the French Commercial Code, that if subscriptions, including those of shareholders, as the case may be, have not absorbed the

- entire issue, the Board of Directors may use, in the order it shall determine, the following options:
- limit the amount of the issue to the amount of subscriptions, it being specified that in the event of an issue of ordinary shares or securities whose primary security is a share, the amount of subscriptions must reach at least three-quarters of the issue decided upon for this limitation to be possible,
 - freely allocate all or part of the unsubscribed shares;
- decides that the issuance price of the ordinary shares that may be issued under this delegation of authority must be at least equal to, at the discretion of the Board of Directors or the Chief Executive Officer:
- either at the last closing price of the Company's share preceding the setting of the issue price, possibly reduced by a maximum discount of 15%;
 - either at the volume-weighted average of the prices of the Company's shares on the regulated market of Euronext in Paris over a period chosen by the Board of Directors or, as the case may be, the Chief Executive Officer comprising between one and five consecutive trading sessions from among the last thirty trading sessions preceding the setting of the issue price, less a maximum discount of 15%;
- decides that the issue price of the securities giving access to the share capital, as the case may be, issued pursuant to this delegation shall be equal to the amount received immediately by the Company, increased by the amount likely to be received by the Company upon the exercise, conversion, redemption or exchange of such securities, or, for each share issued as a result of the issuance of these securities, at least equal to the amount mentioned in the preceding paragraph;
- 6) decides that the Board may not, except with the prior authorization of the General Meeting, make use of this delegation of authority as from the filing by a third party of a proposed public offer for the Company's securities until the end of the offer period;
- 7) decides that the Board of Directors, within the limits set out above, with option of sub-delegation under the conditions provided for by law, will have full powers to implement this delegation of authority, and in particular to:
- to decide to issue shares and/or securities and to determine their characteristics, in particular the amount of the issue, the issuance price and the amount of the premium that may be requested on issue, the terms and conditions of their subscription and payment and their date of entitlement to dividends, and to determine the dates and terms of issue, the nature, number and characteristics of the shares and/or securities to be created and issued;
 - more generally, to determine the characteristics of all securities and, in particular, the terms and conditions for the allotment of shares, the duration of loans that may be issued in the form of bonds, whether they are subordinated or not, the currency of issue, the terms of repayment of the principal, with or without premium, the terms and conditions of redemption and, as the case may be, of purchase, exchange or early redemption, the interest rate, whether fixed or variable, and the date of payment; the remuneration may include a variable portion calculated by reference to factors relating to the Company's

- business and results and a deferred payment in the absence of distributable profits;
- to set the terms and conditions under which the Company will have the right, as the case may be, to purchase or exchange on the stock market, at any time or during specific periods, the securities issued or to be issued immediately or in the future with a view to cancelling them or not, taking into account the legal provisions;
 - provide the possibility to suspend the exercise of rights attached to the shares or securities issued, for up to three (3) months, in accordance with legal and regulatory provisions;
 - to charge the fees related to the capital increase against the related premiums and deduct from this amount the sums necessary to increase the legal reserve;
 - to determine and make all adjustments to take into account the impact of transactions on the Company's share capital or shareholders' equity;
 - record the completion of each capital increase and make the corresponding amendments to the bylaws;
 - generally, enter into any agreement, in particular to ensure the successful completion of the planned issues, take all measures and carry out all formalities necessary for the issue, listing and financial servicing of the securities issued pursuant to this delegation, as well as for the exercise of the rights attached thereto;
- 8) acknowledges that, in the event that the Board of Directors decides to exercise the delegation of authority conferred upon it in this resolution, the Board of Directors will report to the next Ordinary General Meeting, in compliance with the law and the regulations, on the use of the delegation granted under this resolution;
- 9) notes that this delegation renders ineffective, as from the date hereof, any unused portion, as the case may be, of the delegation of authority granted by the General Meeting of June 11, 2025 in its twenty-third resolution.

24. Twenty-fourth Resolution (*Delegation of powers to be granted to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities and/or securities giving access to ordinary shares, without preferential subscription rights, in favor of one or more persons specifically designated by the Board of Directors*). - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings, having reviewed the Board of Directors' report and the Statutory Auditors' special report and acting in accordance with the provisions of the French Commercial Code, especially Articles L.225-129-2, L.22-10-51, L.22-10-52-1, L.225-138 and L.225-92 of said Code:

- 1) delegates to the Board of Directors, with the option to sub-delegate under the conditions provided for by law, its power to issue, without preferential subscription rights, on one or more occasions, in France or abroad, in the proportions and at the times it deems appropriate, either in euros, or in any other currency or currency units established by reference to several currencies, with or without a premium, for consideration or free of charge:
- ordinary shares, and/or
 - securities that are equity securities giving access to other equity securities or to the allocation of debt securities, and/or

- securities, including debt securities, giving access to equity securities to be issued, it being specified that, in accordance with Article L. 228-93 of the French Commercial Code, the securities to be issued may give access to equity securities to be issued by the Company and/or any company that directly or indirectly owns over than half of its share capital or in which it directly or indirectly owns over than half of the share capital;
the subscription of which may be made either in cash or by offsetting claims;
- 2) sets the term of validity of this delegation at eighteen (18) months, starting from the date of this Meeting;
- 3) decides to set the following limits on the amounts of capital increases authorized in the event that the Board of Directors exercises this delegation of authority:
 - the maximum nominal amount of capital increases that may be performed under this delegation may not exceed 29,604,244 euros or the equivalent in any other currency or in any other currency units established by reference to several currencies, it being specified that, in any event, the nominal amount of capital increases carried out pursuant to this resolution may not exceed the limit set by the legal and regulatory provisions applicable at the time of use of this delegation (on an indicative basis, currently 30% of the share capital per year, in accordance with the provisions of Articles L. 225-138 and Article L. 22-10-52-1 of the French Commercial Code, assessed on the date of implementation of the delegation by the Board of Directors) and count toward the overall limit provided for in the thirty-first resolution of this Meeting;
 - added to this cap will be, as the case may be, the nominal value of the ordinary shares to be issued to preserve, in accordance with applicable laws and, as the case may be, contractual provisions that provide for other cases of adjustments, the rights of the holders of securities giving access to the Company's share capital;
- 4) decides to set the following limits on the amounts of debt securities authorized in the event of an issue of securities in the form of debt securities giving immediate or future access to the capital of the Company or other companies:
 - the maximum nominal amount of debt securities of the Company that may be issued pursuant to this delegation may not exceed 200,000,000 euros or the equivalent in any other currency or currency units established by reference to several currencies; it being specified that this cap will be deducted from the overall limit provided for in the thirty-first resolution of this Meeting;
 - this amount shall be increased, as the case may be, by any redemption premium above par and is independent of the amount of the debt securities whose issuance may be decided or authorized by the Board of Directors in accordance with Articles L.228-36-A, L. 228-40, L.228-92 paragraph 3, L.228-93 paragraph 6 and L.228-94 paragraph 3 of the French Commercial Code;
- 5) decides, in accordance with the provisions of Articles L. 22-10-52-1 and R. 22-10-32 of the French Commercial Code, that the issue price of the shares issued under this delegation shall be at least equal to the closing price on the last trading session preceding the setting of the issue price, possibly reduced by a maximum discount of 10%;
- 6) decides to waive the preferential subscription rights of shareholders to ordinary shares and

securities giving access to capital and/or debt securities, in favor of one or more specifically designated persons, and to delegate to the Board of Directors the designation of such persons;

- 7) decides that the Board of Directors cannot, except with the prior authorization of the General Meeting, make use of this delegation of authority as from the filing by a third party of a proposed public offer for the Company's securities until the end of the offer period;
- 8) decides that the Board of Directors shall have, within the limits set out above, with the option of sub-delegation under the conditions provided for by law, will have full powers to implement this delegation of authority and, in particular to:
 - decide on the issue of shares and/or securities and determine their characteristics, in particular the amount of the issue, the issue price and the amount of the premium that may be requested upon issue, the terms and conditions of subscription and payment, and the date on which they will become effective, and determine the dates and terms and conditions of the issue, the nature, the number and characteristics of the shares and/or securities to be created and issued;
 - designate the person(s) for whom the issue is reserved in accordance with Article L.22-10-52-1 of the French Commercial Code;
 - more generally, determine the characteristics of all securities and, in particular, the terms and conditions for the allocation of shares, the term of loans that may be issued in the form of bonds, whether or not they are subordinated, the currency of issue, the terms of repayment of the principal, with or without a premium, the terms and conditions of amortization and, as the case may be, purchase, exchange or early redemption, the interest rates, whether fixed or variable, and the payment date; the remuneration may include a variable portion calculated by reference to factors relating to the Company's business and results and a deferred payment in the absence of distributable profits; determine the terms and conditions under which the Company shall, where applicable, have the option to purchase or exchange on the stock exchange, at any time or during specified periods, the securities issued or to be issued immediately or in the future, with a view to cancelling them or not, in accordance with legal provisions;
 - provide for the option to suspend the exercise of rights attached to shares or securities giving access to the share capital for a maximum period of three (3) months in accordance with legal and regulatory provisions;
 - charge the fees related to the capital increase against the related premiums and deduct from this amount the sums necessary to increase the legal reserve;
 - determine and make any adjustments necessary to take into account the impact of transactions on the Company's share capital or shareholders' equity;
 - record the completion of each capital increase and make the corresponding amendments to the articles of association;
 - in general, enter into any agreement, in particular to ensure the successful completion of the planned issues, take all measures and carry out all formalities necessary for the issue, listing and financial servicing of the securities issued pursuant to this delegation, as well as for the exercise of the rights attached thereto;

- 9) acknowledges that, in the event that the Board of Directors decides to exercise the delegation of authority conferred upon it in this resolution, the Board of Directors will report to the next Ordinary General Meeting, in compliance with the law and the regulations, on the use of the delegation granted under this resolution.
- 10) notes that this delegation renders ineffective, as from the date hereof, any unused portion, as the case may be, of the delegation of authority granted by the General Meeting of June 11, 2025 in its twenty-fourth resolution.

25. Twenty-fifth Resolution (*Delegation of authority to be granted to the Board of Directors to issue ordinary shares and/or securities giving access to the share capital or the allocation of debt securities without preferential subscription rights in favor of a category of persons satisfying determined characteristics*). - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings and having reviewed the Board of Directors' report and the Statutory Auditors' special report and pursuant to the provisions of the French Commercial Code, specifically Articles L. 225-129-2, L.22-10-49, L. 225-138 and L. 228-92:

- 1) delegates to the Board of Directors, with the option to sub-delegate under the conditions provided for by law, its authority to issue, without preferential subscription rights, on one or more occasions, in the proportions and at the times of its choosing, in France and abroad, in euros or in any other currency, or in any other currency units established by reference to several currencies, with or without premium, free of charge or for a price:
 - ordinary shares, and/or
 - securities which are equity securities giving access to other equity securities or to the allocation of debt securities, and/or
 - securities, including debt securities, giving access to equity securities to be issued, it being specified that, pursuant to Article L. 228-93 of the French Commercial Code, the securities to be issued may give access to equity securities to be issued by the Company and/or any company that directly or indirectly owns over than half of its share capital or of which the Company directly or indirectly owns over than half of the share capital;

the subscription for which may be settled either in cash or by offsetting receivables;

- 2) sets the term of validity of this authorization at eighteen (18) months from the date of this General Meeting;
- 3) decides to set the following limits on the amounts of the capital increases authorized in the event of use by the Board of Directors of the present delegation of authority:
 - the maximum nominal amount of capital increases that may be performed under this delegation may not exceed 29,604,244 euros or the equivalent in any other currency, or in any other currency units established by reference to several currencies, it being specified that this maximum amount counts toward the overall limit provided for in the thirty-first resolution of this General Meeting;
 - added to this cap will be, as the case may be, the nominal value of the ordinary shares to

be issued to preserve, in accordance with applicable laws and, as the case may be, contractual provisions that provide for other cases of adjustments, the rights of the holders of securities giving access to the Company's share capital;

- 4) decides to set the following limits on the amounts of debt securities authorized in the event of the issue of securities in the form of debt securities giving immediate or future access to the capital of the Company or of other companies:
 - the maximum nominal amount of debt securities that may be issued pursuant to this delegation may not exceed 200,000,000 euros or the equivalent in any other currency, or in any other currency units established by reference to several currencies; this cap will be deducted from the overall limit referred to in the thirty-first resolution of this Meeting;
 - this amount will be increased, as the case may be, by any redemption premium above par and is independent of the amount of debt securities whose issuance would be decided or authorized by the Board of Directors in accordance with Articles L.228-36-A, L.228-40, L.228-92 paragraph 3, L.228-93 paragraph 6 and L.228-94 paragraph 3 of the French Commercial Code;
- 5) in the event that the Board of Directors makes use of this delegation of authority:
 - decides, in accordance with the provisions of Article L. 225-138 of the French Commercial Code, that the issue price of ordinary shares that may be issued under the scope of this delegation of powers will be set by the Board of Directors and must be at least equal to, at the discretion of the Board of Directors or the Chief Executive Officer:
 - the last closing price of the Company's shares preceding the setting of the issue price, possibly reduced by a maximum discount of 15%,
 - the volume-weighted average price of the share of the Company on the regulated market of Euronext in Paris over a period chosen by the Board of Directors or, as the case may be, the Chief Executive Officer of between one to five consecutive trading sessions chosen from the last thirty trading sessions preceding the setting of the issue price, possibly reduced by a maximum discount of 15%;
 - decides that (i) the issue price of the shares likely to result from the exercise of the securities giving access to the capital issued by virtue of this delegation, or from their conversion, exchange or redemption, may be set, at the discretion of the Board of Directors, by reference to a calculation formula defined by the latter and applicable after the issue of the said securities (for example at the time of their exercise, conversion, redemption or exchange), in which case the maximum discount referred to above may be assessed, if the Board of Directors deems this appropriate, at the date on which such formula is applied (and not at the date of issuance of the security), and (ii) the issue price of the securities giving access to the share capital, as the case may be, issued pursuant to this delegation shall be equal to the amount received immediately by the Company, increased by the amount likely to be received by the Company upon the exercise, conversion, redemption or exchange of such securities, or, for each share issued as a result of the issuance of these securities, at least equal to the amount mentioned in the preceding paragraph;

- decides to waive the shareholders' preferential subscription rights to ordinary shares and securities covered by this resolution in favor of one or more persons belonging to one or more of the following categories of persons:
 - a) natural persons or legal entities, including companies, trusts, investment funds or other investment vehicles, regardless of their form, under French or foreign law, investing on a regular basis in the pharmaceutical, biotechnological or medical technology sector; and/or
 - b) French or foreign companies, institutions or entities of any form, carrying out a significant portion of their business in these sectors or in the pharmaceutical chemical sector or in the field of medical devices or technologies or research in these areas; and/or
 - c) French or foreign investment service providers, or any foreign establishments with equivalent status, likely to guarantee the completion of an issue intended to be placed with the persons referred to in (a) and/or (b) above or within the framework of the implementation of an equity or bond financing line and, in this context, to subscribe to the securities issued.
 - acknowledges that this delegation automatically entails, in favor of the holders of securities giving access to share capital, the express waiver by the shareholders of their preferential subscription right to subscribe to the shares to which these securities will give immediate or future entitlement;
 - decides, in accordance with Article L.225-134 of the French Commercial Code, that if subscriptions, including those of shareholders, as the case may be, have not absorbed the entire issue, the Board of Directors may use, in the order it shall determine, the following options or some of them only:
 - limit the amount of the issue to the amount of subscriptions, it being specified that in the event of an issue of ordinary shares or securities whose primary security is a share, the amount of subscriptions must reach at least three-quarters of the issue decided upon for this limitation to be possible,
 - freely allocate all or part of the unsubscribed securities;
- 6) decide that the Board of Directors, with the option to sub-delegate under the conditions provided for by law, will set the specific list of beneficiaries of this or these capital increases and/or issues of securities reserved within this or these categories of persons and the number of securities to be allocated to each of them;
- 7) decides that the Board of Directors cannot, except with the prior authorization of the General Meeting, make use of this delegation as from the filing by a third party of a proposed public offer for the Company's securities until the end of the offer period;
- 8) decides that the Board of Directors, within the limits set out above, with option of sub-delegation under the conditions provided for by law, will have full powers to implement this delegation, and in particular to:

- to decide to issue shares and/or securities and to determine their characteristics, determine the amount to be issued, the issue price and the amount of the premium that can, if applicable, be demanded at issue, the terms and conditions of their subscription and payment and their date of entitlement to dividends, and to determine the dates and terms of issue, the nature, number and characteristics of the shares and/or securities to be created and issued;
 - to determine the list of the beneficiaries within the categories designated above and the number of securities to be allocated to each beneficiary;
 - in the event of the issue of warrants, to determine the number and characteristics of such warrants and to decide, if it deems appropriate, under the terms and conditions it shall determine, that the warrants may be redeemed or repurchased, or that they shall be allocated free of charge to the shareholders in proportion to their rights in the share capital;
 - more generally, to determine the characteristics of all securities and, in particular, the terms and conditions for the allotment of shares, the duration of loans that may be issued in the form of bonds, whether they are subordinated or not, the currency of issue, the terms of repayment of the principal, with or without premium, the terms and conditions of redemption and, as the case may be, of purchase, exchange or early redemption, the interest rate, whether fixed or variable, and the date of payment; the remuneration may include a variable portion calculated by reference to factors relating to the Company's business and results and a deferred payment in the absence of distributable profits;
 - to provide the possibility to suspend the exercise of rights attached to the shares or securities issued, for up to three (3) months, in accordance with legal and regulatory provisions;
 - to charge the fees related to the capital increase against the related premiums and deduct from this amount the sums necessary to increase the legal reserve;
 - to determine and make all adjustments to take into account the impact of transactions on the Company's share capital or shareholders' equity;
 - record the completion of each share capital increase and make the corresponding amendments to the by-laws;
 - in general, enter into any agreement, in particular to ensure the successful completion of the planned issues, take all measures and carry out all formalities necessary for the issue, listing and financial servicing of the securities issued pursuant to this delegation, as well as for the exercise of the rights attached thereto;
- 9) acknowledges that, in the event that the Board of Directors decides to exercise the delegation of authority conferred upon it in this resolution, the Board of Directors will report to the next ordinary General Meeting, in compliance with the law and the regulations, on the use of the delegation granted under this resolution;
- 10) notes that this delegation renders ineffective, as from the date hereof, any unused portion, as the case may be, of the delegation of authority granted by the General Meeting of June 11, 2025, in its twenty-fifth resolution.

26. Twenty-sixth Resolution (*Delegation of authority to be granted to the Board of Directors to decide on the issue of ordinary shares to be issued immediately or in the future by the Company, without preferential subscription rights in favor of a category of persons satisfying determined characteristics within the framework of an equity financing agreement on the United States stock market known as "At-The-Market" or "ATM Program"*). - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings and having reviewed the Board of Directors' report and the Statutory Auditors' special report and pursuant to the provisions of the French Commercial Code and in particular Articles L. 225-129-2, L. 22-10-49, L. 225-138 and L. 225-92:

- 1) delegates to the Board of Directors, with the option to sub-delegate under the conditions provided for by law, its authority to issue, on one or more occasions, in the proportions and at the times of its choosing, in France and abroad, in euros or in any other currency, or in any other currency units established by reference to several currencies, without preferential subscription rights, ordinary shares in the form of *American Depositary Shares* or *American Depositary Receipts* of the Company;

the subscription for which may be settled either in cash or by offsetting receivables;

- 2) sets the term of validity of this delegation at eighteen (18) months from the date of this General Meeting;
- 3) decides to set the following limits on the amounts of the capital increases authorized in the event of use by the Board of Directors of the present delegation of authority:
 - the maximum nominal amount of capital increases that may be performed under this delegation may not exceed 29,604,244 euros or the equivalent in any other currency, or in any other currency units established by reference to several currencies, it being specified that this cap counts toward the overall limit provided for in the thirty-first resolution of this General Meeting;
 - added to this cap will be, as the case may be, the nominal value of the ordinary shares to be issued to preserve, in accordance with applicable laws and, as the case may be, contractual provisions that provide for other cases of adjustments, the rights of the holders of securities giving access to the Company's share capital;
- 4) if the Board of Directors decides to use this delegation of authority
 - decides, in accordance with the provisions of Article L. 225-138 of the French Commercial Code, that the issuance price of ordinary shares that may be issued under the scope of this delegation of powers will be set by the Board of Directors, with option of sub-delegation under the conditions provided for by law, and shall be at least equal to (at the option of the Board of Directors):
 - either the last closing price of the Company's shares preceding the setting of the issue price, possibly reduced by a maximum discount of 15%, or
 - the volume-weighted average price of the share of the Company on the regulated market of Euronext in Paris over a period chosen by the Board of Directors or, as

the case may be, the Chief Executive Officer of between one to five consecutive trading sessions chosen from the last thirty trading sessions preceding the setting of the issue price, possibly reduced by a maximum discount of 15%;

- decides to waive the shareholders' preferential subscription rights to the shares or securities covered by this resolution in favor to one or more persons belonging to one or more of the following categories of persons
 - any credit institution, any investment service provider, French or foreign, or any foreign institution with an equivalent status, intervening within the framework of an ATM Program set up by the Company (or any equity financing program of the same nature which would replace it) and providing, within this framework, for the subscription of securities issued by the Company;
 - decides, in accordance with Article L.225-134 of the French Commercial Code, that if subscriptions, including those of shareholders, as the case may be, have not absorbed the entire issue, the Board of Directors may use, in the order it shall determine, the following options or some of them only:
 - limit the amount of the issue to the amount of subscriptions, it being specified that in the event of an issue of ordinary shares or securities whose primary security is a share, the amount of subscriptions must reach at least three-quarters of the issue decided upon for this limitation to be possible,
 - freely allocate all or part of the unsubscribed securities;
- 5) decides that the Board of Directors may not, without the prior authorization of the General Meeting, make use of this delegation of authority as from the filing by a third party of a proposed public offer for the Company's securities until the end of the offer period
- 6) decides that the Board of Directors, with the option to sub-delegate under the conditions provided for by law, will set the specific list of beneficiaries of this or these capital increases and/or issues of securities reserved within this or these categories of persons and the number of securities to be allocated to each of them;
- 7) decides that the Board of Directors, within the limits set out above, with option of sub-delegation under the conditions provided for by law, will have full powers to implement this resolution, and therefore to:
- to decide to issue shares and to determine their characteristics, in particular the amount of the issue, the issue price and the amount of the premium that can be requested upon issue, the terms and conditions of their subscription and their date of entitlement, and to determine the dates and terms and conditions of the issue, the nature, number and characteristics of the shares to be issued;
 - to determine the list of the beneficiaries within the categories designated above and the number of securities to be allocated to each beneficiary;
 - to set the terms and conditions under which the Company will, as the case may be, have the right to purchase or exchange on the stock market, at any time or during specific periods, the securities issued or to be issued immediately or in the future with a view to

- cancelling them or not, taking into account the legal provisions;
- to provide for the possibility of suspending the exercise of rights attached to shares or securities giving access to the share capital for a maximum period of three (3) months in accordance with legal and regulatory provisions;
 - to charge the fees related to the capital increase against the related premiums and deduct from this amount the sums necessary to increase the legal reserve;
 - to determine and make all adjustments to take into account the impact of transactions on the Company's share capital or shareholders' equity;
 - record the completion of each share capital increase and make the corresponding amendments to the by-laws;
 - in general, enter into any agreement, in particular to ensure the successful completion of the planned issues, take all measures and carry out all formalities necessary for the issue, listing and financial servicing of the securities issued pursuant to this delegation, as well as for the exercise of the rights attached thereto;
- 8) acknowledges that, in the event that the Board of Directors decides to exercise the delegation of authority conferred upon it in this resolution, the Board of Directors will report to the next ordinary General Meeting, in compliance with the law and the regulations, on the use of the delegation granted under this resolution;
- 9) notes that this delegation renders ineffective, as from the date hereof, any unused portion, as the case may be, of the delegation of authority granted by the General Meeting of June 11, 2025 in its twenty-sixth resolution.

27. Twenty-seventh Resolution (*Delegation of authority to be granted to the Board of Directors to increase the number of securities to be issued in the event of a capital increase with or without preferential subscription rights with excess demand for subscriptions*). - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings and having reviewed the Board of Directors' report and the Statutory Auditors' special report and pursuant to the provisions of the French Commercial Code and in particular Article L. 225-135-1:

- 1) delegates to the Board of Directors, with option of sub-delegation under the conditions provided for by law, its authority to decide, for each of the issues of ordinary shares or securities giving access to the share capital decided pursuant to the twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth and twenty-sixth resolutions, to increase the number of securities to be issued, in accordance with the conditions set out in Articles L. 225-135-1 and R. 225-118 of the French Commercial Code (i.e., to date, within thirty days of the closing of the subscription, at the same price as that used for the initial issue and up to a limit of 15% of the issue price) and within the limit of the ceiling(s) provided for in the resolution pursuant to which the issue is decided, in particular with a view to granting an over-allotment option in accordance with market practices;
- 2) decides that the Board of Directors may not, without the prior authorization of the General Meeting, make use of this authorization as from the filing by a third party of a proposed public offer for the Company's securities until the end of the offer period;

- 3) sets the term of validity of this delegation of authority at twenty-six (26) months from the date of this General Meeting (except for the 24th, 25th and 26th resolutions, for which this delegation is valid for an 18-months period);
- 4) notes that this delegation renders ineffective, as from the date hereof, any unused portion, as the case may be, of the delegation granted by the General Meeting of June 11, 2025 in its twenty-seventh resolution.

28. Twenty-eighth Resolution (*Delegation to be granted to the Board of Directors to increase the capital by issuance of ordinary shares and/or securities giving access to the capital, within the limits set by the applicable legal and regulatory provisions on the date of the capital increase in consideration for contributions in kind of securities or securities giving access to the share capital*) - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings and having reviewed the Board of Directors' report and the Statutory Auditors' special report and pursuant to the provisions of the French Commercial Code and in particular Articles L. 225-147, L. 22-10-49, L. 22-10-53 and L. 228-91 and seq. of said Code:

- 1) authorize the Board of Directors to proceed, on the basis of the statutory auditors' report mentioned in paragraphs 1 and 2 of Article L. 225-147 of the French Commercial Code, to the issuance of ordinary shares or securities giving access to ordinary shares, up to 20% of the share capital, in order to remunerate contributions in kind granted to the Company and consisting of equity securities or securities giving access to the share capital when the provisions of Article L. 22-10-54 of the French Commercial Code are not applicable;
- 2) sets the term of validity of this delegation of authority at twenty-six (26) months, with effect from the date of this Meeting;
- 3) decides that the maximum nominal amount of capital increases that may be carried out under this delegation counts toward the overall limit provided for in the thirty-first resolution of this General Meeting and to the cap mentioned in 1) above will be added, as the case may be, the nominal value of the ordinary shares to be issued to preserve, in accordance with applicable laws and, as the case may be, contractual provisions that provide for other cases of adjustments, the rights of the holders of rights or securities giving access to the Company's share capital;
- 4) decides to set the following limits on the amounts of debt securities authorized in the event of the issue of securities in the form of debt securities giving immediate or future access to the capital of the Company or of other companies:
 - the nominal amount of the debt securities of the Company that may be issued pursuant to this delegation may not exceed 200,000,000 euros or the equivalent in any other currency, or currency units established by reference to several currencies; it being specified that this cap counts toward the overall limit provided for in the thirty-first resolution of this Meeting;
 - this amount will be increased, as the case may be, by any redemption premium above par and is independent of the amount of debt securities whose issuance would be decided or authorized by the Board of Directors in accordance with Articles L.228-36-A, L.228-40, L.228-92 paragraph 3, L.228-93 paragraph 6 and L.228-94 paragraph 3 of the French Commercial Code;

- 5) decides, as necessary, to waive the shareholders' preferential subscription rights to ordinary shares and securities covered by this resolution in favor of the providers of securities;
- 6) decides that the Board of Directors may not, without the prior authorization of the General Meeting, make use of this delegation as from the filing by a third party of a proposed public offer for the Company's shares until the end of the offer period;
- 7) decides that the Board of Directors, within the limits set out above, with option of sub-delegation under the conditions provided for by law, will have full powers to implement this resolution, and in particular to:
 - to decide, on the basis of the contribution auditor's reports referred to in the 1st and 2nd paragraphs of Article L. 225-147 of the French Commercial Code, on the valuation of contributions and the granting of any special benefits;
 - decide to issue shares and/or securities giving immediate or future access to the Company's share capital in consideration for the contributions;
 - determine the list of equity securities and securities giving access to the share capital contributed, approve the valuation of the contributions, set the terms and conditions of issue of the shares and/or securities remunerating the contributions, and, as the case may be, the amount of the balancing cash payment, approve the granting of special benefits, and reduce, if the contributors agree, the valuation of the contributions or the remuneration of the special benefits;
 - to determine the dates and terms of issue, the nature, number and characteristics of the shares and/or securities remunerating the contributions and to modify, during the life of these securities, the said terms and characteristics in compliance with the applicable formalities and to set the terms according to which the rights of the holders of securities giving access to the share capital will be preserved, where applicable; to decide, in addition, in the event of the issue of debt securities, whether or not they will be subordinated (and, where applicable, their rank of subordination);
 - to charge the fees related to the capital increases against the related premiums, and deduct from this amount the sums necessary to increase the legal reserve;
 - to set the terms and conditions under which the Company may, as the case may be, purchase or exchange securities on the stock market at any time or during specific periods, with a view to cancelling them or not, pursuant to legal provisions;
 - to provide the possibility to suspend the exercise of rights attached to shares or securities giving access to the share capital in accordance with legal and regulatory provisions;
 - to determine and make all adjustments to take account of the impact of transactions affecting the Company's share capital or shareholders' equity, in particular in the event of a change in the par value of the share, a capital increase by incorporation of reserves, profits or premiums, a bonus share issue, a stock split or reverse stock split, the distribution of dividends, reserves or premiums or any other assets, amortization of capital, or any other transaction affecting the capital or shareholders' equity (including in the event of a public offering and/or a change of control), and to set any other terms

and conditions to ensure the preservation of the rights of holders of securities giving access to the capital or other rights giving access to the capital (including by way of adjustment in cash);

- record the completion of each capital increase and make the corresponding amendments to the bylaws;
 - generally enter into any agreement, in particular to ensure the successful completion of the planned issues, take all measures and carry out all formalities necessary for the issue, listing and financial servicing of the securities issued pursuant to this delegation, as well as for the exercise of the rights attached thereto;
- 8) acknowledges that, in the event that the Board of Directors decides to exercise the delegation conferred upon it in this resolution, the report of the contribution auditor, if one is drawn up in accordance with Articles L. 225-147 and L. 22-10-53 of the French Commercial Code, will be brought to its attention at the next General Meeting;
- 9) notes that this delegation renders ineffective, as from the date hereof, any unused portion, as the case may be, of the delegation of authority granted by the General Meeting of June 11, 2025 in its twenty-eighth resolution.

29. Twenty-ninth Resolution (*Delegation of authority to be granted to the Board of Directors to decide of any merger-absorption, spin-off, or partial contribution of assets*). - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings, having reviewed the Board of Directors' report and in accordance with the provisions of Articles L. 236-9 II, L. 236-16 and L. 236-22 of the French Commercial Code:

- 1) delegates to the Board of Directors all powers to decide, at the times it deems appropriate, on one or more mergers-absorptions, spin-off or partial contributions of assets carried out in accordance with the provisions of Articles L. 236-1 and seq. of the French Commercial Code;
- 2) decides that the Board of Directors shall have full powers to implement, in accordance with the conditions set by law and the bylaws, this delegation to determine all the terms and conditions of any transaction that may be decided pursuant to this delegation, it being specified that if this transaction requires a capital increase by the Company, such increase must be carried out within the limits set forth in the thirtieth resolution below;
- 3) acknowledges that, in accordance with Article L. 236-9, II, paragraph 4, of the French Commercial Code, one or more shareholders of the Company representing at least 5% of the share capital may apply to the courts, within twenty (20) days of the last publication in accordance with Article R. 236-2 of the French Commercial Code or, as the case may be, the last publication provided for in Article R. 236-3 of the same code, for the appointment of a legal representative for the purpose of convening the General Meeting of the company to vote on the approval of the merger, spin-off, the partial contribution of assets submitted to the spin-off regime or of their sole proposition;
- 4) sets the term of validity of this delegation of authority at twenty-six (26) months, with effect from the date of this General Meeting;

- 5) decides that the Board of Directors may not, without the prior authorization of the General Meeting, make use of this delegation as from the filing by a third party of a proposed public offer for the Company's shares until the end of the offer period;
- 6) notes that this delegation renders ineffective, as from the date hereof, any unused portion, as the case may be, of the delegation granted by the General Meeting of June 11, 2025 in its twenty-ninth resolution.

30. Thirtieth Resolution (*Delegation of powers to be granted to the Board of Directors to issue ordinary shares giving, as the case may be, access to ordinary shares or to the allocation of debt securities (of the Company or of a Group company), and/or securities giving access to ordinary shares (of the Company or of a Group company), in the context of an operation of merger, spin-off or partial contribution of assets decided by the Board of Directors pursuant to the delegation referred to in the twenty-ninth resolution*) - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings, having reviewed the Board of Directors' report and the Statutory Auditors' report, subject to the adoption of the twenty-ninth resolution above, and in accordance with the French Commercial Code and in particular the provisions of Articles L. 225-129 to L. 225-129-2, L. 225-129-5, L. 22-10-49 and L. 228-91 and seq. of said Code:

- 1) delegates to the Board of Directors its power to decide on the issue, on one or more occasions and at the times it deems appropriate, on the French and/or international market, either in euros, or in a foreign currency or any other unit of account established by reference to a set of currencies:
 - ordinary shares, and/or
 - ordinary shares giving right to the allocation of other ordinary shares or debt securities, and/or
 - securities giving access to ordinary shares to be issued;

in consideration for contributions in kind granted to the Company in connection with any merger, spin-off or partial asset contribution decided by the Board of Directors pursuant to the delegation granted under the twenty-ninth resolution above, said shares confer the same rights as existing shares, subject to their dividend entitlement date;

- 2) sets the period of validity of this delegation of authority at twenty-six (26) months, with effect from the date of this Meeting;
- 3) decides, as necessary, to waive, in favor of the shareholders of the absorbed or transferring company, the shareholders' preferential subscription right to these ordinary shares and securities to be issued;
- 4) acknowledges, as necessary, that this delegation automatically entails, in favor of the holders of securities giving access to share capital, the express waiver by the shareholders to their preferential subscription right to subscribe to the shares to which these securities will give immediate or future entitlement;

- 5) decides to set the following limits on the amounts of the capital increases authorized in the event of use by the Board of Directors of the present delegation of authority:
 - the maximum nominal amount of the ordinary shares that may be issued pursuant to this delegation may not exceed 10% of the share capital on the date of the decision to increase the share capital by the Board of Directors, it being specified that this cap counts toward the overall limit of the maximum nominal amount of the shares likely to be issued under the thirty-first resolution of this General Meeting,
 - added to this cap will be, as the case may be, the amount of the additional shares to be issued to preserve, in accordance with applicable laws and, as the case may be, contractual provisions that provide for other cases of adjustments, the rights of the holders of securities and other rights giving access to the share capital;

- 6) decides to set the following limits on the amounts of debt securities authorized in the event of the issue of securities in the form of debt securities giving immediate or future access to the capital of the Company or of other companies:
 - the maximum nominal amount of issues of debt securities giving access to the capital and debt securities that may be issued pursuant to this delegation may not exceed 200,000,000 euros (or the equivalent value of this amount in the event of an issue in another currency), it being specified that this amount will be deducted from the overall limit referred to in the thirty-first resolution,
 - this amount will be increased, as the case may be, by any redemption premium above par and is independent of the amount of debt securities whose issuance would be decided or authorized by the Board of Directors in accordance with Articles L. 228-36-A, L. 228-40, L. 228-92 paragraph 3, L. 228-93 paragraph 6 and L. 228-94 paragraph 3 of the French Commercial Code;

- 7) decides that the Board of Directors cannot, except with the prior authorization of the General Meeting, make use of this delegation as from the filing by a third party of a proposed public offer for the Company's securities until the end of the offer period;

- 8) acknowledges that the Board will have full powers to decide and record the completion of the capital increase in consideration for the transaction, to charge all fees and duties incurred by the capital increase, to deduct them from the premium, if it deems appropriate, the sums necessary to increase the legal reserve, to make the corresponding amendments to the bylaws, to take any decision with a view to admitting the shares and securities issued to trading on Euronext, and, more generally, to do whatever is necessary;

- 9) notes that this delegation renders ineffective, as from the date hereof, any unused portion, as the case may be, of the delegation granted by the General Meeting of June 11, 2025 in its thirtieth resolution.

31. Thirty-first Resolution (Overall limit on the maximum authorized amounts set under the resolutions twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-eighth and thirtieth). - The General Meeting, acting in accordance with the quorum and majority requirements for

extraordinary shareholders' meetings and having reviewed the Board of Directors' report, decides to set:

- 1) at 29,604,244 euros, the total nominal amount of the capital increases that may be carried out pursuant to the twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-eighth and thirtieth resolutions submitted to this Meeting, it being specified that to this limit shall be added, as the case may be, the nominal amount of the capital increase necessary to preserve, in accordance with applicable law and, as the case may be, contractual provisions that provide for other cases of adjustments, the rights of the holders of rights or securities giving access to the Company's share capital;
- 2) at 200,000,000 euros (or the equivalent in any other currency or currency units established by reference to several currencies) the maximum nominal amount of debt securities that may be issued pursuant to the aforementioned resolutions.

32. Thirty-second Resolution (*Delegation of powers to be granted to the Board of Directors to increase the capital by means of the incorporation of reserves, profits and/or premiums*). - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings and having reviewed the Board of Directors' report and pursuant to the provisions of Articles L. 225-129-2, L. 225-130 and L. 22-10-50 of the French Commercial Code:

- 1) delegates its competence to the Board of Directors, with the option of sub-delegation under the provisions provided by law, its authority to decide to increase the share capital on one or more occasions, in the periods and according to the methods it may determine, by means of the incorporation, successive or simultaneous, into capital of reserves, profits, premiums or other amounts admitted for capitalization, by the issue and free share allocation or by raising the face value of existing ordinary shares or combining these two methods;
- 2) decides that, in the event that this delegation is used by the Board of Directors, in accordance with the provisions of Article L. 22-10-50 of the French Commercial Code, if the capital increase takes the form of a free allocation of shares, the rights attached to fractional shares may not be traded or assigned and that the corresponding equity securities will be sold; the proceeds of the sale will be allocated to the holders of the rights within the period prescribed by the regulations;
- 3) sets the term of validity of this authorization at twenty-six (26) months from the date of this General Meeting;
- 4) decides that the total nominal amount of the capital increase carried out under this resolution must not exceed the nominal amount of 14,802,122 euros, it being specified that this ceiling is set independently and separately from the capital increase ceilings resulting from the issues of ordinary shares or securities authorized by the other resolutions submitted to this Meeting and by the resolutions adopted and still in force at any previous General Meeting, and that this ceiling shall be increased, where applicable, by the nominal value of the shares to be issued to preserve, in accordance with the law, the rights of holders of securities giving access to shares;

- 5) decides that the Board of Directors cannot, except with the prior authorization of the General Meeting, make use of this delegation as from the filing by a third party of a proposed public offer for the Company's shares until the end of the offer period;
- 6) confers upon the Board of Directors, with option of sub-delegation, all powers in order to implement this resolution and, generally, to take all measures and fulfill all formalities required for the successful completion of each share capital increase, to record the completion and to amend the by-laws accordingly;
- 7) notes that this delegation renders ineffective, as from the date hereof, any unused portion, as the case may be, of the delegation granted by the General Meeting of June 11, 2025 in its thirty-second resolution.

33. Thirty-third Resolution (*Delegation of powers to be granted to the Board of Directors to increase the share capital by the issue of ordinary shares and/or securities giving access to the capital, without preferential subscription rights in favor of the members of a company savings plan pursuant to Articles L. 3332-18 and seq. of the French Labor Code*) - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings and having reviewed the Board of Directors' report and the Statutory Auditors' special report, voting pursuant to Articles L. 22-10-49, L. 225-129-6, L. 225-138-1 and L. 228-92 of the French Commercial Code and L. 3332-18 and seq. of the French Labor Code:

- 1) delegates its authority to the Board of Directors in order, at its own discretion, to increase the share capital on one or more occasions through the issue of ordinary shares or securities giving access to the equity securities to be issued of the Company, in favor of members of one or more group or company employee savings plans established by the Company and/or affiliated French or international companies under the conditions of Article L. 225-180 of the French Commercial Code and of Article L. 3344-1 of the French Labor Code;
- 2) withdraws, in favor of these individuals, any preferential subscription right to shares which may be issued pursuant to this delegation;
- 3) sets the validity of this delegation at twenty-six (26) months from the date of this General Meeting;
- 4) limits the maximum nominal amount of the increase(s) that may be performed under this delegation at 2% of the share capital at the date of this General Meeting, this amount being independent of any other cap provided for in relation to delegated capital increases, it being specified that this amount will be added, as the case may be, to the additional amount of the ordinary shares to be issued to preserve, in accordance with applicable law and the contractual provisions that provide for other cases of adjustments, the rights of the holders of securities giving access to the Company's share capital;
- 5) decides that the price of the shares to be issued pursuant to point 1/ of this delegation may not be less of more than 30% or 40% where the period of unavailability provided for in the plan pursuant to Articles L. 3332-25 and L. 3332-26 of the French Labor Code is greater than or equal to ten years, to an average of the share price listed during the 20 trading sessions preceding the day of the decision setting the opening date for the subscription, nor higher than this average opening price of the shares for the 20 trading days prior to the decision setting the date for the opening of subscriptions, nor may it be higher than this average;

- 6) decides, pursuant to the provisions of Article L.3332-21 of the French Labor Code, that the Board of Directors may allocate to the beneficiaries defined in the first paragraph above, free shares already issued or to be issued, or other securities giving access to the Company's capital that have already been issued or are to be issued in respect of (i) any employer contribution that may be paid pursuant to the regulations governing group or company savings plans and/or (ii) if applicable, any discount;
- 7) decides that the Board of Directors shall have full powers, with the option of sub-delegation under the conditions provided for by law, to implement the present delegation, to take all measures to determine the various terms and conditions of the transaction and to carry out all necessary formalities;
- 8) notes that this delegation renders ineffective, as from the date hereof, any unused portion, as the case may be, of the delegation of authority granted by the General Meeting of June 11, 2025 in its thirty-third resolution.

34. Thirty-fourth Resolution (*Delegation of powers to be granted to the Board of Directors to issue warrants (BSA), subscription and/or acquisition of new and/or existing warrants (BSAANE) and/or subscription and/or acquisition of new and/or existing redeemable warrants (BSAAR) without preferential subscription right in favor of a category of persons*) - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings and having reviewed the Board of Directors' report and the Statutory Auditors' special report and pursuant to the provisions of Articles L. 225-129-2, L. 22-10-49, L. 225-138 and L. 228-91 and seq. of the French Commercial Code:

- 1) delegates its authority to the Board of Directors to proceed, on one or more occasions, in the proportions and at the time it deems appropriate, both in France and abroad, to the issue of warrants (BSA), subscription and/or acquisition of new and/or existing warrants (BSAANE) and/or subscription and/or acquisition of new and/or existing redeemable warrants (BSAAR) without preferential subscription rights reserved for the categories of persons defined below;
- 2) sets the term of validity of this delegation at eighteen (18) months from the date of this General Meeting;
- 3) decides that the maximum nominal amount of shares to which the warrants issued pursuant to this delegation give entitlement may not exceed 0.5% of the share capital on the day the Board of Directors decides to grant them. To this cap will be added, as the case may be, the nominal value of ordinary shares to be issued to preserve, in accordance with applicable law and, as the case may be, contractual provisions that provide for other cases of adjustments, the rights of the holders of BSA, BSAANE and/or BSAAR. This maximum amount is independent from all maximum amounts set by the other resolutions of this General Meeting;
- 4) decides that the subscription and/or acquisition price of the shares acquired by exercising the warrants shall be at least equal to the average closing price of the Company's shares for the 20 trading sessions preceding the decision to issue the warrants;
- 5) decides to waive the shareholders' preferential subscription rights to the BSAs, BSAANEs and BSAARs to be issued, to the benefit of the following categories of persons: corporate officers, scientific committee members, employees of the company and persons associated with the

company and the French or foreign companies related to the company, via a service agreement or as a consultant, in accordance with Article L.225-180 of the French Commercial Code;

- 6) stipulates that this delegation means that the shareholders waive their preferential subscription rights to shares that may be issued by the exercising of warrants to the holders of BSAs, BSAANEs and/or BSAARs;
- 7) decides that if subscriptions have not absorbed the entire BSA, BSAANE and/or BSAAR issue, the Board of Directors may exercise the following options:
 - limit the amount of the issue to the amount of subscriptions,
 - freely allocate all or part of the non-subscribed BSAs, BSAANEs and/or BSAARs to persons covered by the categories defined above;
- 8) decides that the Board of Directors shall be granted all necessary powers, under the terms set by the law and stipulated above, to issue BSAs, BSAANEs and/or BSAARs and in particular to:
 - set the specific list of beneficiaries within the categories of persons defined above, the nature and number of warrants to be allocated to each beneficiary, the number of shares to which each warrant shall give entitlement, the issue price of the warrants and the subscription and/or acquisition price of the shares to which the warrants give entitlement under the terms outlined above, it being specified that the issue price of the warrants will be established according to market conditions and on the basis of expert opinion, the terms and deadlines for the subscription and exercise of the warrants, the associated adjustment mechanisms and, more generally, all terms and conditions with respect to the issue;
 - prepare an additional report describing the final terms and conditions of the transaction;
 - conduct the necessary share acquisitions within the framework of the share buyback program and to allocate them via the allocation plan;
 - record the completion of the capital increase resulting from the exercising of the BSAs, BSAANEs and/or BSAARs and to amend the Bylaws accordingly;
 - at its sole discretion, impute the cost of the capital increase to the amount of the associated premiums and deduct the necessary sums from this amount to bring the statutory reserve to one tenth of the new share capital after each increase;
 - delegate, under the conditions provided for by law, the powers required to enact the capital increase, and to delay the capital increase, within the limits and according to the terms and conditions previously set by the Board of Directors;
 - and, more generally, perform all tasks required in similar matters.
- 9) notes that this delegation renders ineffective, as from the date hereof, any unused portion, as the case may be, of the delegation of authority granted by the General Meeting of June 11, 2025 in its thirty-fourth resolution.

35. Thirty-fifth Resolution (Authorization to be granted to the Board of Directors to allocate free shares to members of staff and/or certain corporate officers of the Company). - The General Meeting, acting

in accordance with the quorum and majority requirements for extraordinary shareholders' meetings and having reviewed the Board of Directors' report and the Statutory Auditors' special report:

- 1) authorizes the Board of Directors, on one or more occasions, in accordance with Articles L. 22-10-49, L. 225-197-1 and seq., L. 22-10-59 and L. 22-10-60 of the French Commercial Code, to allocate existing or future ordinary shares in the Company, reserved for:
 - members of staff of the Company or companies or economic interest groups that are directly or indirectly related to it as defined by Article L. 225-197-2 of the French Commercial Code,
 - and/or corporate officers who meet the conditions set out in Article L. 225-197-1 of the French Commercial Code;
- 2) sets the term of validity of this authorization at eighteen (18) months from the date of this General Meeting;
- 3) decides that the total number of shares that can be allocated pursuant to this authorization may not exceed 9.5% of the share capital on the date the shares are granted, it being specified that it may not exceed the maximum percentage provided for by the regulations in force on the date of the grant decision and that this limit shall count against the overall nominal amount of shares that may be purchased or subscribed under the thirty-sixth resolution; these limits will exclude, if applicable, the par value of any capital increase required to preserve the rights of the beneficiaries of share awards in the event of transactions involving the Company's capital during the vesting period;
- 4) decides that the allocation of shares to beneficiaries will become definitive after a vesting period to be determined by the Board of Directors, which may not be less than one year;
- 5) decides that the Board of Directors shall determine, in accordance with the law, at the time of each grant decision, the period during which beneficiaries are required to hold the Company's shares, which period shall run from the date of final allocation of the shares, it being specified that this holding period may not be less than one year. However, in the event that the vesting period is two years or more, the holding period may be waived by the Board of Directors;
- 6) decides, by way of exception, that final allocation will take place before the end of the vesting period in the event that the beneficiary is classified as disabled under the second and third categories set out in Article L. 341-4 of the French Social Security Code, or a similar case abroad;
- 7) notes and resolves, in the event of the free allotment of shares to be issued, that this authorization entails the waiver by the shareholders, in favor of the beneficiaries of the allotments of ordinary shares to be issued, of their preferential subscription right to subscribe to the ordinary shares to be issued as and when the shares are definitively allotted, and will entail, where applicable, at the end of the vesting period, a capital increase by incorporation of reserves, profits or premiums in favor of the beneficiaries of the said shares allocated free of charge, and a corresponding waiver by the shareholders in favor of the beneficiaries of the shares allocated free of charge of the part of the reserves, profits and premiums thus incorporated;
- 8) delegates all powers to the Board of Directors, with the option of sub-delegation, to:
 - set the terms and, if applicable, the award criteria and performance criteria for the shares;

- determine the identity of the beneficiaries and the number of shares allocated to each;
 - if applicable:
 - record the existence of sufficient reserves and, upon each allocation of shares, transfer to a reserve account the sums required to pay up the new shares to be granted;
 - at the appropriate time, determine the capital increases by means of incorporation of reserves, premiums or profits relating to the issue of new free shares granted;
 - conduct the necessary share acquisitions within the framework of the share buyback program and allocate them via the allocation plan;
 - determine the impact on beneficiaries' rights of transactions affecting the share capital or likely to affect the value of shares allocated and enacted during the vesting period and, as a result, to modify or adjust, if necessary, the number of shares granted to preserve the beneficiaries' rights;
 - determine, within the limits set by this resolution, the duration of the acquisition period;
 - decide whether or not to establish a holding obligation at the end of the vesting period and, if applicable, determine its duration and take all necessary measures to ensure that the beneficiaries comply with it;
 - and generally, in connection with the legislation in effect, perform all duties that the implementation of this authorization may require;
- 9) notes that this delegation of authority supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 1, 2025 in its thirty-fifth resolution.

36. Thirty-sixth Resolution (*Authorization to be granted to the Board of Directors to grant stock options to employees and/or certain corporate officers of the Company or related companies or economic interest groups*). - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings and having reviewed the Board of Directors' report and the Statutory Auditors' special report:

- 1) authorizes the Board of Directors, under the provisions of Articles L. 22-10-49, L. 225-177 to L. 225-185 and L. 22-10-56 to L. 22-10-58 of the French Commercial Code, to grant the beneficiaries indicated below, on one or more occasions, options giving access to new shares in the Company to be issued in respect of a capital increase or to the purchase of existing shares in the Company as a result of buybacks carried out under the terms set by law;
- 2) sets the term of validity of this authorization at eighteen (18) months from the date of this General Meeting;
- 3) decides that the beneficiaries of these options may only be:
 - firstly, some or all members of staff, or certain categories of staff and, where appropriate, those companies or economic interest groups related to it under the conditions of Article L. 225-180 of the French Commercial Code,

- secondly, corporate officers who meet the conditions set out in Article L. 225-185 of the French Commercial Code;
- 4) decides that the total number of options that may be granted under this authorization shall not entitle the holders to subscribe for or purchase a number of shares exceeding 9.5% of the share capital existing on the date the options are granted, it being specified that it may not exceed the maximum percentage provided for by the regulations in force on the date of the grant decision and that this limit shall count against the overall nominal amount of shares that may be granted as provided for in the thirty-fifth resolution; to these amounts will be added, as necessary, the par value of any capital increase necessary to preserve the rights of the beneficiaries of the options in the event of transactions involving the Company's capital, pursuant to the law and, if applicable, any contractual stipulations providing for other forms of preservation;
 - 5) decides that the subscription and/or acquisition price of the shares to be paid by the beneficiaries will be set on the day the options are granted by the Board of Directors in accordance with the regulations in effect and must not be less than the average opening price of the shares for the twenty trading days prior to the grant decision;
 - 6) decides that no options may be granted during the blackout periods set out in the regulations;
 - 7) notes that this authorization includes, in favor of the beneficiaries of options giving access to shares, an express waiver by shareholders of their preferential subscription rights to subscribe to the shares that will be issued as and when the options are exercised;
 - 8) delegates all powers to the Board of Directors to set the other terms and conditions for the granting of options and their exercise, in particular to:
 - determine the conditions under which the options shall be granted and to draft the list or categories of beneficiaries as scheduled above; to determine, where appropriate, the seniority and performance conditions that must be met by these beneficiaries; to determine the conditions under which the price and number of shares must be adjusted, particularly in the presumptions set out under Articles R. 225-137 to R. 225-145 and R. 22-10-37 of the French Commercial Code;
 - define the exercise period(s) for the options granted, with the understanding that the term of the options may not exceed a period of ten years from the grant date;
 - provide the option to temporarily suspend the exercise of options for a maximum period of three (3) months in the event that financial transactions are performed involving the exercise of a right attached to shares;
 - if applicable, conduct the necessary share acquisitions within the framework of the share buyback program and to allocate them via the option plan;
 - proceed with all acts and formalities required to make final those capital increases that may, if necessary, be performed pursuant to the authorization granted by this resolution; amend the by-laws accordingly and generally to do whatever is necessary;
 - at its own discretion and if it sees fit, charge the fees of capital increases against the associated premiums and deduct the necessary sums from this amount to increase the legal reserve to one tenth of the new share capital after each increase;

- 9) notes that this delegation renders ineffective, as from the date hereof, any unused portion, as the case may be, of the delegation granted by the General Meeting of June 11, 2025 in its thirty-sixth resolution.

37.Thirty-seventh Resolution (*Overall limit on the maximum authorized amounts set under the resolutions thirty-fifth and thirty-sixth*). - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings and having reviewed the Board of Directors' report and the Statutory Auditors' special report,

- decides that the shares that may be allocated by the Board of Directors under the thirty-fifth resolution and the options that may be granted by the Board of Directors under the thirty-sixth resolution shall not entitle the beneficiaries to receive, subscribe for or purchase a total number of shares exceeding 9.5% of the share capital existing on the date the shares or the options are granted, it being specified that to this limit shall be added, as the case may be, the nominal amount of the capital increase necessary to preserve, in accordance with applicable law and, as the case may be, contractual provisions that provide for other cases of adjustments, the rights of the holders of rights or securities giving access to the Company's share capital.

38.Thirty-eighth Resolution (*Ratification of the amendment to Article 18 and Article 21 of the Company's bylaws*). - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings and having reviewed the Board of Directors' report and the amended articles of the bylaws, ratifies the decision of the Board of Directors at its meeting of March 26, 2026, to amend Articles 18 and 21 of the Company's bylaws in accordance with the provisions of decree n°2026-94 of February 13, 2026, and the resulting amendments to Article 18 and Article 21 of the bylaws.

The new wording of Article 18 of the Company's bylaws is reproduced below:

Previous wording	New wording
<p>[...]</p> <p>The notice of meeting must <u>also</u> specify the conditions under which shareholders may vote by post, and the <u>place where, and terms and conditions</u> according to which they may obtain postal vote forms.</p> <p>The notice of meeting may be sent, where applicable, with a proxy form and a postal voting form, under the conditions specified in Article 21 of these Articles of Association, or with a postal voting form only, under the conditions specified in Article 21 of these Articles of Association.</p> <p>[...]</p>	<p>[Unchanged]</p> <p>The notice of meeting must specify the conditions under which shareholders may vote by post, and the conditions according to which they may obtain postal vote forms.</p> <p>Paragraph removed</p> <p>[Unchanged]</p>

--	--

The new wording of the second paragraph of Article 21 of the Company's bylaws is reproduced below:

Previous wording	New wording
<p><i>If the Board of Directors decides at the time of convening the meeting to allow the transmission of voting or proxy forms by electronic means, the electronic signature of these forms may result from a reliable process for identifying the shareholder, guaranteeing its link with the remote form to which its signature is attached. The vote thus expressed before the meeting by this electronic means, as well as the acknowledgement of receipt given, will be considered as non-revocable writings and opposable to all. The proxy is however revocable in the same way as those required for the appointment of the proxy. In the event of a transfer of ownership of securities occurring before midnight (Paris time) on the second business day preceding the meeting, the Company will invalidate or modify accordingly, as the case may be, the proxy or the vote cast before the meeting by this electronic means.</i></p>	<p><i>If the Board of Directors decides at the time of convening the meeting to allow the transmission of voting or proxy forms by electronic means, the electronic signature of these forms may result from a reliable process for identifying the shareholder, guaranteeing its link with the remote form to which its signature is attached. The vote thus expressed before the meeting by this electronic means, as well as the acknowledgement of receipt given, will be considered as non-revocable writings and opposable to all. The proxy is however revocable in the same way as those required for the appointment of the proxy. In the event of a transfer of ownership of securities occurring before midnight (Paris time) on the fifth business day preceding the meeting, the Company will invalidate or modify accordingly, as the case may be, the proxy or the vote cast before the meeting by this electronic means.</i></p>

39. Thirty-ninth Resolution (Amendment to Article 15 of the Company's bylaws to set the age limit for the Chief Executive Officer at 70 years). - The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary shareholders' meetings and having reviewed the Board of Directors' report, decides to amend Article 15 of the Company's bylaws to set the age limit for the Chief Executive Officer at 70 years and to add the following paragraph to Article 15 of the Company's bylaws:

"No person aged 70 or over may be appointed as Chief Executive Officer. When this age limit is reached during the term of office, the duties of the Chief Executive Officer shall automatically cease at the end of the Ordinary General Meeting of Shareholders convened to approve the financial statements for the financial year in which the Chief Executive Officer reaches the age limit."

Ordinary resolutions

40. Fortieth Resolution (Powers to complete formalities). - The General Meeting grants all powers to the bearer of an original, a copy or an excerpt of these minutes to carry out all mandatory formalities with respect to registration and publication.

4. REPORT OF THE BOARD OF DIRECTORS ON THE RESOLUTIONS SUBMITTED TO THE ANNUAL GENERAL MEETING

The purpose of this report is to outline the reasons for the resolutions submitted for your approval at the combined general meeting to be held on June 3, 2026 (the "Annual General Meeting").

FIRST TO FOURTH RESOLUTIONS

Approval of the annual financial statements for the year ended December 31, 2025

Approval of the consolidated financial statements for the year ended December 31, 2025

Allocation of income for the year ended December 31, 2025

Allocation of the accumulated deficit to the "Additional paid-in capital"

It is proposed to you, under the terms of the first, second, third and fourth resolutions, to approve the annual and consolidated financial statements for the year ended December 31, 2025, to allocate the result and to charge the accumulated deficit brought forward to the "additional paid-in capital" account.

First resolution – Approval of the annual financial statements for the year ended December 31, 2025

The Board of Directors proposes an ordinary resolution to receive and adopt the statutory financial statements for the year ended December 31, 2025, showing a loss of EUR (123,018,389.41).

The 2025 statutory financial statements are available on the Company's website at the following address: <https://dbv-technologies.com/events/2026-annual-general-meeting/>.

Second resolution – Approval of the consolidated financial statements for the year ended December 31, 2025

The Board of Directors proposes an ordinary resolution to receive and adopt the consolidated financial statements for the year ended December 31, 2025, showing a loss of USD (146,946,904.70) (US GAAP) and of USD (147,156,369.31) (IFRS).

The 2025 consolidated financial statements are available on the Company's website at the following address: <https://dbv-technologies.com/events/2026-annual-general-meeting/>.

Third resolution – Allocation of income for the year ended December 31, 2025

The Board of Directors proposes an ordinary resolution to fully allocate the whole of the net loss for the financial year ended December 31, 2025, totaling € (123,018,389.41), to the "Accumulated deficit" line, which would result in a negative balance of € (190,148,327.46).

No distribution of dividends or income has occurred in the past three financial years.

Fourth resolution – Allocation of the accumulated deficit to the "Additional paid-in capital"

The Board proposes to charge € 190,148,327.46 of the retained earnings account for the financial year ended December 31, 2025, of the total amount of € (190,148,327.46), to the "additional paid-in capital" account which, before this charge, amounts to €312,354,226.86.

Consequently, the “additional paid-in capital” account would amount to € 122,205,899.40.

FIFTH RESOLUTION

Statutory auditors’ special report on regulated agreements

The Board proposes to approve the statutory auditors’ report on related party transactions referred to in Article L. 225-38 of the French Commercial Code.

SIXTH RESOLUTION

Renewal of the term of office of KPMG, as statutory auditor

The term of office of KPMG as statutory auditor will expire at the end of the Annual General Meeting. If renewed, the term of KPMG will expire at the end of the General Meeting to be held in 2032 to approve the financial statements for the previous financial year. Representatives of KPMG are expected to be present online at the Annual General Meeting. According to French rules, they will not be invited to comment on the renewal of their mandate.

SEVENTH TO TENTH RESOLUTIONS

Ratification of the provisional appointment of Ms. Philina Lee, as Director

Renewal of Mr. Michael j. Goller, as Director

Renewal of Mr. Daniel Tassé, as Director

Renewal of Ms. Maïlys Ferrère, as Director

Seventh resolution - Ratification of the provisional appointment of Ms. Philina Lee, as director

Ms. Philina Lee has been provisionally appointed as Board Member, by the Board of Directors at its meeting on October 30, 2025, to replace Mr. Daniel Soland who left the Board of Directors on September 18, 2025.

The Board proposes, under the recommendation of the Nomination and Governance Committee, to ratify such provisional appointment, for the remaining term of office of her predecessor, expected to expire at the end of the General Meeting to be held in 2028 to approve the financial statements for the previous financial year.

Ms. Philina Lee has agreed to serve if her provisional appointment is ratified.

Ms. Philina Lee’s biography is provided in section 3.2.1.1. of the Company’s 2025 Universal Registration Document.

Eighth resolution - Renewal of Mr. Michael j. Goller, as director

The term of office of Mr. Michael J. Goller as Director expires at this Annual General Meeting.

Upon the recommendation of the Nominating and Governance Committee, the Board of Directors proposes to renew the term as Director of Mr. Michael J. Goller for a period of three years, to expire at the end of the General Meeting occurring in 2029.

Mr. Michael J. Goller's biography is provided in section 3.2.1.1. of the Company's 2025 Universal Registration Document.

Ninth resolution - Renewal of Mr. Daniel Tassé, as director

The term of office of Mr. Daniel Tassé as Director expires at this Annual General Meeting.

Upon the recommendation of the Nominating and Governance Committee, the Board of Directors proposes to renew the term as Director of Mr. Daniel Tassé for a period of three years, to expire at the end of the General Meeting occurring in 2029.

Mr. Daniel Tassé's biography is provided in section 3.2.1.1. of the Company's 2025 universal registration document.

Tenth resolution - Renewal of Ms. Maïlys Ferrère, as director

The term of office of Ms. Maïlys Ferrère as Director expires at this Annual General Meeting.

Upon the recommendation of the Nominating and Governance Committee, the Board of Directors proposes to renew the term as Director of Ms. Maïlys Ferrère for a period of three years, to expire at the end of the General Meeting occurring in 2029.

Ms. Maïlys Ferrère's biography is provided in section 3.2.1.1. of the Company's 2025 Universal Registration Document.

ELEVENTH TO THIRTEENTH RESOLUTIONS

Approval of the information set out in section I of Article L.22-10-9 of the French Commercial Code on the compensation of corporate officers for the year ended December 31, 2025

Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Mr. Michel de Rosen, Chairman of the Board of Directors

Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Mr. Daniel Tassé, Chief Executive Officer

You are requested, pursuant to the eleventh, twelfth and thirteenth resolutions and in application of the provisions of Article L. 22-10-34 of the French Commercial Code, to approve all remuneration paid or granted during fiscal year 2025, respectively, to all the corporate officers of the Company, to Monsieur Michel de Rosen, Chairman of the Board of Directors, and to Monsieur Daniel Tassé, Chief Executive Officer.

All of these components of remuneration are set out in detail in paragraph 3.4 of the Company's 2025 Universal Registration Document.

Eleventh resolution - Approval of the information set out in section i of article L.22-10-9 of the French commercial code on the compensation of corporate officers for the year 2025

In accordance with Article L.22-10-34 of the French Commercial Code, our Board is required to present to shareholders the information referred to in Article L.22-10-9 I of the French Commercial Code mentioned in the corporate governance report included in section 3.4 of the 2025 Universal Registration Document.

Twelfth resolution - Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Michel de Rosen, Chairman of the Board of Directors

In accordance with Article L.22-10-34 II of the French Commercial Code, our Board is required to present to shareholders the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Michel de Rosen, Chairman of the Board of Directors, as presented in section 3.4 of the 2025 Universal Registration Document.

Thirteenth resolution - Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Mr. Daniel Tassé, Chief Executive Officer

In accordance with Article L. 22-10-34 II of the French Commercial Code, our Board is required to present to shareholders the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Daniel Tassé, Chief Executive Officer, as presented in section 3.4 of the 2025 Universal Registration Document.

FOURTEENTH RESOLUTION

Advisory opinion on the compensation of named executive officers other than the Chief Executive Officer

Pursuant to the fourteenth resolution, and in accordance with the provisions of U.S. law (Section 14A of the Exchange Act of 1934) and SEC rules, you are requested to approve, on a non-binding advisory basis, the compensation of our named executive officers other than the Chief Executive Officer.

These compensation elements are set out in detail in section 3.4 of the 2025 Universal Registration Document. The compensation policy for executive officers implemented by the Company is intended to attract and retain very talented executives within our industry.

Unlike the vote to approve the compensation of the Chief Executive Officer (which is the subject of the thirteenth resolution referred to above), this is an advisory vote which will not be binding on our Compensation Committee or Board of Directors, our Compensation Committee and Board of Directors will carefully review the results of the shareholder vote. Our Compensation Committee and Board of Directors will consider potential shareholders' concerns and take them into account in future determinations concerning compensation of our named executive officers.

FIFTEENTH RESOLUTION

Increase of the total remuneration (annual budget) allocated to Directors

Under the terms of the fifteenth resolution, it is proposed to you, in accordance with the provisions of Article L. 225-45 of the French Commercial Code, to increase the amount allocated to directors from EUR 900,000 to EUR 1,150,000.

This increase is intended for the purposes of the revised structure of the 2026 Director compensation policy, as approved by the Board of Directors at its meeting on February 13, 2026, and to be maintained for the next financial years, unless the Board submits other updates to the shareholders' approval at a General Meeting.

The new directors' remuneration policy is set out in detail in Section 3.4 of the 2025 Universal Registration Document.

SIXTEENTH TO EIGHTEENTH RESOLUTIONS

Approval of the compensation policy for the Chairman of the Board of Directors for the year ending December 31, 2026

Approval of the compensation policy for the Directors for the year ending December 31, 2026

Approval of the compensation policy for the Chief Executive Officer and Deputy Chief Executive Officer for the year ending December 31, 2026

You are requested, pursuant to the sixteenth, seventeenth and eighteenth resolutions and in application of the provisions of Article L. 22-10-8 of the French Commercial Code, to approve the remuneration policy applicable for fiscal year 2026 respectively to the Chairman of the Board of Directors, to the directors and to the Chief Executive Officer.

This remuneration policy is presented in detail in section 3.4 of the 2025 Universal Registration Document.

Sixteenth resolution – Approval of the compensation policy for the Chairman of the Board of Directors for the year ending December 31, 2026

In accordance with Article L. 22-10-8 of the French Commercial Code, you are requested to approve the compensation policy to be allocated to the Chairman of the Board of Directors, as set out in section 3.4 of the 2025 Universal Registration Document.

Seventeenth resolution – Approval of the compensation policy for the Directors for the year ending December 31, 2026

In accordance with the provisions of Article L. 22-10-8 of the French Commercial Code, you are requested to approve the compensation policy to be allocated to the Directors, as set out in section 3.4 of the 2025 Universal Registration Document.

Eighteenth resolution - Approval of the compensation policy for the Chief Executive Officer for the year ending December 31, 2026

In accordance with the provisions of Article L. 22-10-8 of the French Commercial Code, you are requested to approve the compensation policy to be allocated to the Chief Executive Officer, as set out in section 3.4 of the 2025 Universal Registration Document.

NINETEENTH RESOLUTION

Authorization to be granted to the Board of Directors to buy back company shares on the Company's behalf pursuant to Article L.22-10-62 of the French Commercial Code

Pursuant to the nineteenth resolution, you are requested to authorize the Board of Directors, for a period of eighteen months, to buy back, on one or more occasions and at the times of its choosing, Company shares up to the limit of 5% of the number of shares comprising the share capital at the date of purchase, adjusted, if necessary, to take into account any increase or reduction in capital that may have taken place during the course of the program.

This authorization would cancel the authorization granted to the Board of Directors under the nineteenth ordinary resolution of the General Meeting of June 11, 2025.

The shares may be bought back in order to:

- support the secondary market for or the liquidity of the Company's shares through a liquidity agreement with an investment service provider, in accordance with the standard practice accepted by the regulations, in which context the number of shares taken into account for the calculation of the aforementioned limit corresponds to the number of shares purchased, after deduction of the number of shares resold;
- provide coverage to meet obligations arising from stock option plans and/or free share allocation plans (or similar plans) for the group's employees and/or corporate officers, as well as all share allocations arising under company or group employee savings plans (or similar

plans), employee profit-sharing plans and/or any other form of share allocation arrangement for the group's employees and/or corporate officers;

- hedge the securities giving access to the Company's shares, pursuant to current regulations;
- hold the purchased shares and ultimately return them for future exchange or as payment under external growth transactions;
- where applicable, cancel all or part of the shares acquired; or
- more generally, operate for any purpose that may be authorized by law or any market practice that may be permitted by the market authorities, it being specified that, in such a case, the Company would inform its shareholders by way of a press release.

The acquisition, sale, exchange or transfer of these shares may be executed by any means, including through the purchase of share blocks, at the time deemed appropriate by the Board of Directors.

The Board may not, without the prior authorization of the General Meeting, use this authorization during a public offer period initiated by a third party for the shares of the Company until the end of the offer period.

The Company does not intend to use options or derivatives.

The maximum purchase price would be set at €25 per share and the overall ceiling would be set at €370,053,000.

In the event of a capital transaction, in particular a stock split or reverse split, or the allocation of free shares to shareholders, the above-mentioned amount will be adjusted in the same proportions (multiplier coefficient equal to the ratio between the number of shares comprising the capital before the transaction and the number of shares after the transaction).

TWENTIETH RESOLUTION

Delegation to be granted to the Board of Directors to reduce the share capital by cancellation of shares pursuant to Article L.22-10-62 of the French Commercial Code

You are requested to grant all powers to the Board of Directors for the purpose of cancelling, on one or more occasions, all or part of the Company shares acquired as a result of the buy back authorized by the shareholders pursuant to the nineteenth resolution. The shares to be canceled pursuant to this authorization shall not exceed 10% of our share capital in any 24-month period.

The Board proposes the shareholders authorize the Board of Directors to, for a period of 18 months, pursuant to Article L. 22-10-62 of the French Commercial Code:

- cancel, at its discretion, on one or more occasions, up to 10% of the capital calculated on the date of the decision to cancel, less any shares canceled during the last 24 months, shares the Company holds or may hold following buy-backs performed pursuant to Article L. 22-10-62 of the French Commercial Code and to reduce the share capital accordingly in compliance with legal and regulatory provisions in force; and
- carry out all necessary operations to perform such cancellations and the resulting reductions of the share capital, accordingly amending the Company's Bylaws and fulfilling all formalities required.

TWENTY-FIRST TO THIRTY-SECOND RESOLUTIONS

Financial authorizations

DBV Technologies is a late-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing our novel Viaskin technology platform. Developing, seeking regulatory approval of, and commercializing product candidates requires significant resources. Given its historical operating losses and reliance on external financings, the Company may seek additional capital as it prepare for the launch of Viaskin Peanut, if approved.

We may also need to secure capital to accelerate development of a promising new product candidate, to expand the geographical reach of our commercialization, or to pursue a promising business development opportunity.

A range of financing options is available in the marketplace, and we wish to be able to pursue the most appropriate financing for our company. We understand the need to be good stewards of our investors' money and will continue to seek financing with a reasonable risk profile and attention to investor dilution. We also need to have resolutions that ensure consistency between U.S. (SEC) and French (AMF) market practices and regulatory standards.

Therefore, the Board of Directors wishes to be able to benefit from authorization to:

- increase the share capital with cancellation of preferential subscription rights in favor of one or more persons to be designated by the Board of Directors (24th resolution);
- to increase the share capital with cancellation of subscription rights in favor of categories of persons meeting specified characteristics, with an applicable discount of up to 15% (25th resolution); and
- increase the share capital with cancellation of subscription rights in favor of categories of persons meeting specified characteristics within the framework of an equity financing agreement on the United States stock market known as “At-The-Market” or “ATM Program” (26th resolution).

We are therefore seeking approval at the Annual General Meeting of the following resolutions that would allow raising capital even in adverse situations, to best ensure the continuity of our operations. These resolutions will be suspended in case of a hostile takeover attempt.

The proposed financial authorizations would provide our Board of Directors with additional flexibility to respond quickly to changes in market conditions and thereby be able to obtain financing under the best possible conditions.

The financial delegations of authority presented for your approval at the Annual General Meeting are subject to the following important limitations:

- the maximum global nominal amount of the share capital increases which may be completed pursuant to Resolutions 22, 23, 24, 25, 26, 28 and 30 cannot exceed EUR29,604,244, i.e. approximately 100% of our share capital as of the date on which the Board of Directors decided to convene the Annual General Meeting (March 26, 2026);
- any share capital increase pursuant to Resolution 27, which grants a customary over-allotment option for any issuance pursuant to Resolutions 21, 22, 23, 24, 25, and 26, would be at the same price as, and limited to a maximum of 15% of, the initial issuance;

- the aggregate amount of share capital increases pursuant to Resolution 32 cannot exceed EUR14,802,122, i.e. approximately 50% of our share capital as of March 26, 2026.

These authorizations would be granted for a period of twenty-six months (except for the twenty-fourth, twenty-fifth and twenty-sixth resolutions for which the authorizations would be valid for a period of eighteen months).

The Board of Directors would exercise these authorizations in accordance with the Company's best interests and needs and shall not exercise them if a third party files a proposed tender offer for the Company's securities, until the end of the offer period.

Twenty-first Resolution – Delegation of authority to be granted to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities and/or securities giving access to ordinary shares with preferential subscription rights

The purpose of this delegation of authority is to enable the Company to obtain financing at any time through the issuance of ordinary shares and any type of securities giving, by any means, immediately and/or in the future, access to ordinary shares, by calling on the Company's shareholders. The Company's shareholders will be awarded, under the applicable legal provisions and in proportion to their ownership interest in the Company's share capital, a preferential right to subscribe for new shares or securities.

The Company intends to use this delegation of authority to raise funds and have the financial flexibility necessary to enable it to execute its strategic objectives, including, but not limited to, with respect to financing potential external growth. In particular, the implementation of this authorization could provide us with quick access to a source of financing and allow us to respond quickly to changes in market conditions.

The share capital increases carried out pursuant to this authorization cannot exceed EUR 29,604,244, i.e. approximately 100% of our share capital as of March 26, 2026. In the case of issuances of debt securities, the nominal amount of any issuances will be limited to EUR 200,000,000.

The Board of Directors would be granted with all powers to implement this authorization.

The Board cannot, unless authorized in advance by the General Meeting, make use of this delegation in a period of public offering initiated by a third party targeting the securities of the Company until the end of the offering period.

This delegation of authority would be granted for a 26-month period.

This delegation supersedes, as from the date hereof, the unused portion, if applicable, of the delegation of authority granted by the General Meeting of June 11, 2025, in its twenty-first resolution.

Twenty-second resolution – Delegation of authority to be granted to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities, and/or securities giving access to equity securities to be issued, without preferential subscription rights by means of a public offer excluding the offers set out in paragraph 1 of Article L.411-2 of the French Monetary and Financial Code, and/or as consideration for securities in the context of a public exchange offer

The purpose of this delegation is to confer on the Board of Directors the necessary authority to issue through a public offering ordinary shares and/or any type of securities giving access, by any means, immediately or in the future, to ordinary shares.

Any issuance pursuant to this delegation would be carried out without shareholders' preferential subscription rights. However, shareholders could be granted a priority subscription period in accordance with applicable French law.

The issue price to be determined by the Board pursuant to this Resolution shall be at least equal to, at the discretion of the Board of Directors or the Chief Executive Officer:

- the last closing price of the Company's share preceding the determination of the issue price, possibly reduced by a maximum discount of 15%; or
- the weighted average of the prices of the last trading sessions chosen by the Board of Directors, or the Chief Executive Officer, between one and five consecutive trading sessions among the last thirty trading sessions, possibly reduced by a maximum discount of 15%.

It is proposed that the aggregate maximum nominal amount of the ordinary shares that may be issued pursuant to this authorization would be set at EUR 29,604,244, i.e., approximately 100% of our share capital as of March 26, 2026. This amount would provide the Company with sufficient flexibility in pursuing our strategic objectives and would provide quick access to sources of financing, in a similar manner to U.S. companies, and allow us to respond quickly to changes in market conditions.

In the case of issuances of debt securities, the nominal amount of any issuances will be limited to EUR 200,000,000.

The amount of any debt securities issued will be subject to (and deducted from) the global limit of EUR 200,000,000, and the amount of any share capital increase will be subject to the global limit of EUR 29,604,244, in each case as approved pursuant to Resolution 31.

The Board of Directors would be granted the all powers to implement this authorization.

The Board cannot, unless authorized in advance by the General Meeting, make use of this delegation in a public offering period initiated by a third party targeting the securities of the Company until the end of the offering period.

This delegation of authority would be granted for a 26-month period.

This delegation supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 11, 2025, in its twenty-second resolution.

Twenty-third resolution – Delegation of authority to be granted to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities, and/or securities giving access to equity securities to be issued, without preferential subscription rights by means of a public offer referred to in paragraph 1 of Article L.411-2 of the French Monetary and Financial Code

The goal of this delegation of authority is to allow the Company to issue ordinary shares and any type of securities giving access, by any means, immediately and/or in the future, to ordinary shares, in one or more private placements to qualified investors or to a limited circle of investors (less than 150) as described in paragraph 1° of Article L. 411-2 of the French Monetary and Financial Code.

The shareholders' preferential subscription right to ordinary shares and/or to securities conferring entitlement to the share capital would be cancelled.

The aggregate nominal amount of the ordinary shares that may be issued may not exceed EUR 29,604,244 i.e. approximately 100% of our share capital as of March 26, 2026, and not to exceed the limit determined by applicable laws and regulations at the time of the implementation of this delegation (on an indicative basis, currently 30% of the Company's share capital per year).

In the case of issuances of debt securities, the nominal amount of any issuances will be limited to EUR 200,000,000.

The amount of any securities issued under Resolution 23 will be subject to (and deducted from) the global limits pursuant to Resolution 31.

The issue price to be determined by the Board pursuant to this Resolution shall be at least equal to, at the discretion of the Board of Directors or the Chief Executive Officer:

- the last closing price of the Company's share preceding the determination of the issue price, possibly reduced by a maximum discount of 15%; or
- the weighted average of the prices of the last trading sessions chosen by the Board of Directors, or the Chief Executive Officer, between one and five consecutive trading sessions among the last thirty trading sessions, possibly reduced by a maximum discount of 15%.

The Board of Directors would have all powers necessary to implement this delegation.

The Board cannot, unless authorized in advance by the General Meeting, make use of this delegation in a period of public offering initiated by a third party targeting the securities of the Company until the end of the offering period.

This delegation of authority would be granted for a 26-month period.

This delegation supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 11, 2025, in its twenty-third resolution.

Twenty-fourth resolution – Delegation of powers to be granted to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities and/or securities giving access to ordinary shares, without preferential subscription rights in favor of one or more persons specifically designated by the Board of Directors

The goal of this delegation of authority is to allow the Company to issue ordinary shares and any type of securities giving access, by any means, immediately and/or in the future, to ordinary shares, to one or more persons to be designated by the Board of Directors.

The shareholders' preferential subscription right to ordinary shares and/or to securities giving access to the share capital would be cancelled.

The aggregate par value of the ordinary shares that may be issued pursuant to this delegation may not exceed EUR 29,604,244 i.e. approximately 100% of our share capital as of March 26, 2026, and not to exceed the limit determined by applicable laws and regulations at the time of the implementation of this delegation (on an indicative basis, currently 30% of the Company's share capital per year).

In the case of issuances of debt securities, the nominal amount of any issuances will be limited to EUR 200,000,000.

The amount of any securities issued under Resolution 24 will be subject to (and deducted from) the global limits pursuant to Resolution 31.

Pursuant to the French Commercial Code, the issue price of the shares issued under this delegation shall be at least equal to the closing price on the last trading session preceding the setting of the issue price, possibly reduced by a maximum discount of 10%.

The Board of Directors would be granted with all powers necessary to implement this delegation.

The Board cannot, unless authorized in advance by the General Meeting, make use of this delegation in a public offering period initiated by a third party targeting the securities of the Company until the end of the offering period.

This delegation of authority would be granted for an 18-month period.

This delegation supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 11, 2025, in its twenty-fourth resolution.

Twenty-fifth resolution – Delegation of authority to be granted to the Board of Directors to issue ordinary shares, giving, as the case may be, access to ordinary shares or the allocation of debt securities (of the Company or a group company) and/or securities giving access to ordinary shares (of the Company or a group company), without preferential subscription rights in favor of a category of persons satisfying determined characteristics

Under this delegation, the issues would be carried out in favor of categories of persons, in particular in accordance with the provisions of Articles L. 225-129-2, L. 225-138 and L. 228-92 of the French Commercial Code.

It is proposed to set the maximum aggregate nominal amount of ordinary shares that may be issued pursuant to this delegation at EUR 29,604,244, i.e. approximately 100% of our share capital as of March 26, 2026.

In the case of issuances of debt securities, the nominal amount of any issuances will be limited to EUR 200,000,000.

The amount of any debt securities issued will be subject to (and deducted from) the global limit of EUR200,000,000, and the amount of any share capital increase will be subject to the global limit of EUR29,604,244, i.e. approximately 100% of our share capital on the date of March 26, 2026, in each case as approved pursuant to Resolution 31.

The issue price of Ordinary Shares that may be issued under the scope of this delegation of powers will be set by the Board of Directors and must be at least equal to, at the discretion of the Board of Directors or the Chief Executive Officer:

- the last closing price of the Company's shares preceding the setting of the issue price, possibly reduced by a maximum discount of 15%, or
- the volume-weighted average of the Company's share price on the Euronext Paris regulated market over a period determined by the Board of Directors of between one to five consecutive trading days, chosen from the 30 trading days preceding the pricing date, which may be reduced by a maximum discount of 15%.

The shareholders are asked to waive shareholders' preferential subscription rights to the Ordinary Shares and securities that would be issued by virtue of this delegation, and to reserve this subscription for the following category of persons:

- natural person(s) or legal entity(ies), including companies, trusts, investment funds or other investment vehicle(s), regardless of their form, under French or foreign law, investing on a regular basis in the pharmaceutical, biotechnological or medical technology sector; and/or
- French or foreign companies, institutions or entities of any form, carrying out a significant portion of their business in these sectors or in the pharmaceutical chemical sector or in the field of medical devices or technologies or research in these areas; and/or
- French or foreign investment service provider(s), or any foreign establishment(s) with equivalent status, likely to guarantee the completion of an issue intended to be placed with the persons referred to in (a) and/or (b) above or within the framework of the implementation of an equity or bond financing line and, in this context, to subscribe to the securities issued.

If the subscriptions have not absorbed the entirety of the issue, the Board of Directors may make use of the following options:

- limit the amount of the issue to the amount of the subscriptions, where applicable within the limits laid down by the regulations,
- freely allocate all or part of the unsubscribed securities among the categories of persons selected.

The Board of Directors would thus have full authority to implement this delegation and would report to the next ordinary general meeting, in accordance with statute and regulations, on the use of the delegation granted pursuant to this resolution.

The Board cannot, unless authorized in advance by a general meeting, make use of this delegation in a period of public offering initiated by a third party targeting the securities of the Company until the end of the offering period.

This delegation of authority would be granted for an 18-month period.

This delegation supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 11, 2025, in its twenty-fifth resolution.

Twenty-sixth resolution – Delegation of authority to be granted to the Board of Directors to decide on the issue of ordinary shares to be issued immediately or in the future by the Company, without preferential subscription rights in favor of a category of persons satisfying determined characteristics within the framework of an equity financing agreement on the United States stock market known as "At-The-Market" or "ATM Program"

On recommendation of the management of the Company, the Board of Directors is requesting the necessary authority to issue Ordinary Shares in the form of American Depositary Shares or American Depositary Receipts of the Company within the framework of an equity financing agreement on the United States stock market known as "At-The-Market" or "ATM Program". Any ATM Program implemented by the Company would be strictly limited to the issuance of ordinary shares in the form of American Depositary Shares or American Depositary Receipts of the Company which would be sold on the Nasdaq Stock Market LLC or any other ADS trading market, without any public offering in France or in Europe.

It is proposed that the maximum aggregate nominal amount of the ordinary shares that may be issued pursuant to this delegation may not exceed EUR 29,604,244, i.e. approximately 100% of our share capital as of March 26, 2026.

In accordance with the provisions of Article L. 225-138 of the French Commercial Code, the issue price of Ordinary Shares that may be issued under the scope of this delegation of powers will be set by the Board of Directors and must be at least equal to, at the discretion of the Board of Directors or the Chief Executive Officer, either:

- the last closing price of the Company's shares preceding the setting of the issue price, possibly reduced by a maximum discount of 15%, or
- the volume-weighted average of the Company's share price on the regulated market of Euronext Paris over a period determined by the Board of Directors of between one to five consecutive trading sessions chosen from among the last 30 trading sessions preceding the setting of the issue price, possibly reduced by a maximum discount of 15%. Under this delegation, the issuances would be carried out for the benefit of categories of persons, in particular in accordance with the provisions of Articles L. 225-129 et seq. of the French Commercial Code (Code de commerce) and, in particular, of its Articles L. 225-129-2, L. 225-135, L. 225-138 and L. 228-91 et seq. of the French Commercial Code (Code de commerce), and of Article L. 22-10-49 of the French Commercial Code (Code de commerce).

The shareholders are asked to waive shareholders' preferential subscription rights to the Ordinary Shares and securities that would be issued by virtue of this delegation, and to reserve this subscription for the following category of persons:

- any credit institution, any investment service provider, French or foreign, or
- any foreign institution with an equivalent status, intervening within the framework of an ATM Program set up by the Company (or any equity financing program of the same nature which would replace it) and providing, within this framework, for the subscription of securities issued by the Company. Unless previously authorized by the General Meeting, the Board of Directors may not make use of this proposed delegation as from the filing by a third party of a draft public offer targeting the Company's securities and until the end of the offer period.

This delegation of authority would be granted for an 18-month period.

This delegation supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 11, 2025, in its twenty-sixth resolution.

Twenty-seventh resolution – Delegation of authority to be granted to the Board of Directors to increase the number of securities to be issued in the event of a capital increase with or without preferential subscription rights, in the event of excess demand

It is proposed to you, within the framework of the twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth and twenty-sixth resolutions, to allow the Board of Directors, with the ability to sub-delegate as permitted by law, to grant a customary over-allotment option, within thirty (30) days following the closing of the subscription, under the conditions laid down by Articles L. 225-135-1 and R. 225-118 of the French Commercial Code and within the limits of the ceilings set by the Annual General Meeting.

Any share capital increase pursuant to this delegation would be at the same price as, and limited to a maximum of 15% of, the initial issuance, which is a standard level for over-allotment options, as per market practice.

The Board of Directors would not, without the prior authorization of the General Meeting, make use of this delegation as from the filing by a third party of a draft public offer for the Company's shares until the end of the offer period.

This delegation of authority would be granted for a 26-month period (except for the 24th, 25th and 26th resolutions, for which this delegation is valid for an 18-month period).

This delegation supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 11, 2025, in its twenty-seventh resolution.

Twenty-eighth resolution – Delegation to be granted to the Board of Directors to increase the share capital by issuance of ordinary shares and/or securities giving access to the share capital within the limits set by the applicable legal and regulatory provisions on the date of the capital increase in consideration for contributions in kind of securities or securities giving access to the share capital

In order to facilitate external growth transactions, you are requested to allow the Board of Directors to increase the share capital in consideration for contributions in kind of equity securities or securities giving access to the capital.

The maximum nominal amount of share capital increases to be completed, immediately or in the future, may not exceed 20% of the share capital of the Company on the date of the decision to increase the share capital by the Board. This limit is set without taking into account the par value of the ordinary shares to be issued, if applicable, in relation to adjustments carried out in order to protect the rights of holders of securities and other rights giving access to capital, in accordance with legal and regulatory requirements.

In the case of issuances of debt securities, the nominal amount of any issuances will be limited to EUR 200,000,000.

The nominal amount of any share capital increase that may be carried out in application of this resolution will be deducted from the overall limit set forth in Resolution 31.

This delegation of authority would be granted for a 26-month period.

This delegation supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 11, 2025, in its twenty-eighth resolution.

Twenty-ninth resolution – Delegation of authority to be granted to the Board of Directors to decide on any merger-absorption, spin-off or partial contribution of assets

You are requested to delegate authority to the board of directors of the Company to decide on any merger-absorption, split or partial contribution of assets in accordance with the provisions of Articles L. 236-1 et seq. of the French Commercial Code, pursuant to the provisions of Article L. 236-9 II of the same Code.

This delegation of authority would be granted for a 26-month period.

This delegation supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 11, 2025, in its twenty-ninth resolution.

Thirtieth resolution – Delegation of authority to be granted to the Board of Directors to issue ordinary shares giving, as the case may be, access to ordinary shares or to the allocation of debt securities (of the Company or of a group company), and/or securities giving access to ordinary shares (of the Company or of a group company), in the context of a merger, spin-off or partial contribution of assets decided by the Board of Directors pursuant to the delegation referred to in the twenty-ninth resolution

It is proposed to you, subject to the adoption of the twenty-ninth resolution, to delegate to the Board of Directors the authority to decide to issue, on one or more occasions, ordinary shares of the Company and/or any type of securities giving access, by any means, immediately and/or in the future, to ordinary shares of the Company, in compensation for contributions in kind granted to the Company as part of any merger, demerger or partial contribution of assets decided by the Board of Directors pursuant to the delegation granted under Resolution 29, such shares conferring the same rights as existing shares, said shares conferring the same rights as old shares subject to their date of use.

It is proposed to you to waive, to the benefit of the shareholders of the absorbed company or the contributing company, any preferential subscription right attached to the ordinary shares or securities to be issued.

The maximum nominal amount of share capital increases to be completed, immediately or in the future, may not exceed 10% of the share capital of the Company on the date of the decision to increase the share capital by the Board. This limit is set without taking into account the par value of the ordinary shares to be issued, if applicable, in relation to adjustments carried out in order to protect the rights of holders of securities and other rights giving access to capital, in accordance with legal and regulatory requirements as well as applicable contractual provisions.

The nominal amount of all issuances of debt securities to be completed giving access to the Company's share capital will not exceed EUR 200,000,000 (or the corresponding value of this amount for an issuance in a foreign currency). This amount will be increased, if applicable, for any redemption premium above nominal value and will be deducted from the overall limit set forth in Resolution 31 below. This limit does not apply to securities the issuance of which is decided or authorized by the Board of Directors in accordance with Articles L. 228-36-A, L. 228-40, L. 228-92 paragraph 3, L. 228-93 paragraph 6 and L. 228-94 paragraph 3 of the French Commercial Code.

This delegation of authority would be granted for a 26-month period.

This delegation supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 11, 2025, in its thirtieth resolution.

Thirty-first resolution – Overall limit on the maximum authorized amounts set under the resolutions twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-eighth and thirtieth

It is proposed that you set the total par value of any shares that may be issued under the 22nd, 23rd, 24th, 25th, 26th, 28th and 30th Resolutions at EUR 29,604,244, i.e. approximately 100% of our share capital as of March 26, 2026.

It is also proposed that you set at EUR 200,000,000 (or the equivalent of this amount in the event of an issue in another currency) maximum nominal amount of debt securities that may be issued pursuant to these resolutions.

The Board of Directors believe that this amount strikes the correct balance between protecting our existing shareholders and providing the Company with the financial flexibility necessary to accomplish its strategic goals, and is in line with the flexibility available to comparable U.S. companies.

Thirty-second resolution – Delegation of authority to be granted to the Board of Directors to increase the capital by means of the incorporation of reserves, profits and/or premiums

You are requested to allow the Board of Directors to increase the share capital by means of the incorporation into capital of reserves, profits, premiums or other amounts admitted for capitalization, by the issue and free share allocation or by raising the face value of existing Ordinary Shares or combining these two methods.

The total par value of any Ordinary Shares or securities giving access to Ordinary Shares that may be issued under this delegation may not exceed EUR 14,802,122, i.e. approximately 50% of our share capital as of March 26, 2026, not including the aggregate par value of the share capital increase required in order to preserve, in accordance with the law and, where applicable, with contractual provisions setting out other preservation mechanisms, the rights of holders of rights or securities granting access to the Company's share capital.

This delegation of authority would be granted for a 26-month period.

This delegation supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 11, 2025, in its thirty-second resolution.

THIRTY-THIRD RESOLUTION

Delegation of authority to be granted to the Board of Directors to increase the capital by the issue of ordinary shares and/or securities giving access to the share capital, without preferential subscription rights in favor of the members of a company savings plan pursuant to Articles L.3332-18 and seq. of the French Labor Code

You are requested to vote on the thirty-third resolution, pursuant to the provisions of Article L. 225-129-6 of the French Commercial Code, to authorize the Board of Directors to increase the share capital through the issuance of shares and securities for the benefit of employees who are members of a company savings plan (*plan d'épargne groupe*).

Under this delegation, it is proposed that you delegate to the Board of Directors your authority to increase the share capital, on one or more occasions, by issuing ordinary shares or securities granting access to the Company's share capital for the benefit of members of one or more company or group savings plans established by the Company and/or by French or foreign companies affiliated with it under the conditions set forth in Article L. 225-180 of the French Commercial Code and Article L. 3344-1 of the French Labour Code.

In accordance with the law, the shareholders' preferential subscription right to the shares or securities would be eliminated for the benefit of the members of a company savings plan (*plan d'épargne entreprise*).

The aggregate nominal amount of share capital increases that would be carried out pursuant to this delegation of authority would not exceed 2% of the share capital at the date of this Annual General Meeting (this amount is separate to any other maximum amounts set by other authorizations relating to capital increases) To this amount would be added, where applicable, the nominal amount of the capital increase necessary to preserve, in accordance with the law and with any applicable contractual provisions providing for other preservation arrangements, the rights of the holders of securities giving entitlement to equity securities of the Company.

It is specified that, in accordance with the provisions of Article L. 3332-19 of the French Labour Code, the price of the shares to be issued under this delegation may not be more than 30% (or 40% if the vesting period stipulated by the scheme pursuant to Articles L. 3332-25 and L. 3332-26 of the French Labor Code is greater than or equal to ten years) below the average opening price of our Ordinary Shares for the 20 trading days prior to the decision setting the date for the opening of subscriptions, nor may it be higher than this average.

This delegation of authority would be granted for a 26-month period.

This delegation supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 11, 2025, in its thirty-third resolution.

THIRTY-FOURTH TO THIRTY-SEVENTH RESOLUTIONS

Equity resolutions

In order to continue a share ownership policy for employees that is incentive-based and liable to support the company's development, you are being asked to renew the authorizations and delegations enabling the Board of Directors to grant share subscription warrants, to award stock options and/or to award free shares.

Pursuant to Resolution 34 of the General Meeting of June 11, 2025, the Board of Directors was authorized to grant share warrants. As such authorization shall expire on December 11, 2026, in order to continue our equity compensation program beyond such date, pursuant to Resolution 34 below, you are requested to renew this prior authorization to the Board of Directors to grant share warrants for the 18-month period following the date of this Annual General Meeting.

Pursuant to Resolutions 35 and 36 of the General Meeting of June 11, 2025, the Board of Directors was authorized to grant, respectively, (i) stock options to subscribe for or purchase Ordinary Shares, and (ii) free Ordinary Shares. As such authorizations will expire on December 11, 2026, in order to continue our equity compensation program beyond such date, pursuant to Resolutions 35 and 36 below, you are requested to renew these prior authorizations to the Board of Directors to grant, respectively, stock options and free Ordinary Shares for the 18-month period following the date of this Annual General Meeting.

The grants of stock options and free Ordinary Shares under Resolutions 35 and 36 are subject to the limitation set forth in Resolution 37. Pursuant to Resolution 37, the aggregate amount of share capital increases that may result from the implementation of Resolutions 35 and 36 may not exceed 9.5% of the share capital at grant date(s).

Thirty-fourth resolution – Delegation of authority to be granted to the Board of Directors to issue warrants (BSA), subscription and/or acquisition of new and/or existing warrants (BSAANE) and/or subscription and/or acquisition of new and/or existing redeemable warrants (BSAAR) without preferential subscription rights in favor of a category of persons

To continue to attract and retain highly talented directors with deep industry knowledge and experience, we must be able to offer our directors compensation in line with market standards, which include an equity-based component. However, pursuant to French law, non-employee directors may not be granted stock options or free shares. As a result, the right to subscribe for BSAs is a key element of our current non-employee director compensation.

This delegation of authority is critical to our business strategy because it enables us to continue issuing BSAs, which is vital to our ability to attract and retain highly talented directors, compete with compensation arrangements provided by our U.S.-based peers and strengthen the alignment of our directors' interests with those of our shareholders.

The Company is also seeking authorization to grant BSAs to persons bound to the Company or one of its subsidiaries by a consultancy agreement who, pursuant to French law, cannot be granted stock options or free shares. In certain circumstances, it is important for the Company to be able to offer a long-term compensation element to such persons in order to engender loyalty in our highly competitive industry and align their incentives with the long-term interests of our shareholders.

You are requested to grant to the Board of Directors full powers for the purposes of proceeding with the issuance of BSA, BSAANE and/or BSAAR for the benefit of categories of persons.

The Board of Directors would have the competence to proceed with the issue of:

- new stock warrants (BSA),
- subscription and/or acquisition of new and/or existing stock warrants (BSAANE),
- subscription and/or acquisition of new and/or existing redeemable stock warrants (BSAAR).

The BSA, BSAANE and/or BSAAR may be issued on one or more occasions, in the proportions and at the time it deems appropriate by the Board, and would confer the right to subscribe for and/or to purchase shares of the Company at a price determined by the Board at the time of the issuance decision, in accordance with the procedures for determining the price set out below.

The total nominal amount of shares to which the warrants issued pursuant to this delegation give entitlement may not exceed 0.5% of the share capital on the date of the allocation decision. To this maximum amount will be added, as necessary, the nominal amount of the capital increase necessary to preserve the rights of the holders of rights or securities giving access to the Company's capital, pursuant to the law.

This maximum amount is separate from all maximum amounts set by the other resolutions of this Annual General Meeting.

The issue price of the warrant would be determined by the Board of Directors under market conditions and on the basis of an expert's opinion.

The subscription and/or acquisition price of the shares to which the warrants would confer entitlement shall be at least equal, after taking into account the issue price of said warrants, to the average of the closing prices of the Company's share over the 20 trading sessions preceding the date of the decision to issue the warrants.

You are requested to resolve to cancel your preferential subscription right in favor of the following categories of persons: the corporate officers, the members of the scientific committee and the employees of the Company, as well as any person bound by a service or consultancy agreement with the Company or with French or foreign companies which are affiliated with the Company within the meaning of Article L.225-180 of the French Commercial Code.

This delegation would entail the shareholders' waiver of their preferential subscription right to the Company's shares likely to be issued upon exercise of the warrants for the benefit of the holders of BSA, BSAANE and/or BSAAR.

The Board cannot, unless authorized in advance by the Annual General Meeting, make use of this delegation in a period of public offering initiated by a third party targeting the securities of the Company until the end of the offering period.

If subscriptions do not cover the entire issue, the Board of Directors may exercise the following options:

- limit the amount of the issue to the amount subscribed, where applicable within the limits laid down by the regulations,
- freely allocate, within the categories of persons defined above, all or part of the unsubscribed BSA, BSAANE and/or BSAAR.

The Board of Directors shall be granted all necessary powers, under the terms set by the law and stipulated above, to issue BSAs, BSAANEs and/or BSAARs and in particular to:

- set the specific list of beneficiaries within the categories of persons defined above, the nature and number of warrants to be allocated to each beneficiary, the number of shares to which each warrant shall give entitlement, the issue price of the warrants and the subscription and/or acquisition price of the shares to which the warrants give entitlement under the terms outlined above, the terms and deadlines for the subscription and exercise of the warrants, the associated adjustment mechanisms and, more generally, all terms and conditions with respect to the issue;
- prepare an additional report describing the final terms and conditions of the transaction;
- conduct the necessary share acquisitions within the framework of the share buyback program and allocate them via the allocation plan;
- record the completion of the capital increase resulting from the exercising of the BSAs, BSAANEs and/or BSAARs and amend the Bylaws accordingly;
- at its sole discretion, impute the cost of the capital increase to the amount of the associated premiums and deduct the necessary sums from this amount to bring the statutory reserve to one tenth of the new share capital after each increase;
- delegate, under the conditions provided for by law, the powers required to enact the capital increase, and to delay the capital increase, within the limits and according to the terms and conditions previously set by the Board of Directors;
- and, more generally, perform all tasks required in similar matters.

The validity of this delegation is set at 18 months from the date of this Annual General Meeting.

This delegation supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 11, 2025, in its thirty-fourth resolution.

Thirty-fifth resolution – Authorization to be granted to the Board of Directors to allocate for free existing and/or to be issued shares to employees and/or certain corporate officers of the Company or related companies or economic interest groups

In order to attract and retain the high-quality executives and key employees, the Company wishes to be able to continue to proceed with the free award of shares.

It is proposed that you grant a delegation of authority to the Board of Directors for the purpose of granting free shares to the employees of the Company and of the companies affiliated with it and/or to certain corporate officers.

Such grants would be reserved for:

- members of staff of the company or companies or economic interest groups that are directly or indirectly related to it as defined by Article L. 225-197-2 of the French Commercial Code;
- and/or corporate officers who meet the conditions set out in Article L. 225-197-1 of the French Commercial Code.

The total number of shares that can be assigned free of charge pursuant to this authorization will not exceed 9.5% of the share capital on the date of the grant decision, it being specified that it may not exceed the maximum percentage provided for by the regulations in force on the date of the grant decision and that this limit shall count against the overall nominal amount of shares that may be purchased or subscribed under the thirty-sixth resolution. This limit will exclude, if applicable, the par

value of any capital increase required to preserve the rights of the beneficiaries of bonus share awards in the event of transactions involving the Company's capital during the vesting period.

The grant of shares to beneficiaries will become definitive after a vesting period to be determined by the Board of Directors, which may not be less than one year.

Beneficiaries shall, where applicable, be required to hold these shares for a period, set by the Board of Directors, at least equal to that necessary to ensure that the cumulative duration of the vesting and, where applicable, holding periods cannot be less than two years.

By way of exception, final allocation will take place before the end of the vesting period in the event that the beneficiary is classified as disabled under the second and third categories set out in Article L. 341-4 of the French Social Security Code.

This authorization shall imply that shareholders waive their preferential subscription rights to subscribe to newly issued shares through the capitalization of reserves, share premium and profits.

Thus, the Board shall have, within the limits set out above, full powers to

- set the terms and conditions and, where applicable, the criteria governing the allocation of shares;
- determine the identity of the beneficiaries of the free allocations from among the persons meeting the conditions set out above, as well as the number of shares allocated to each of them;
- where applicable, verify the existence of sufficient reserves and, at the time of each allocation, carry out the transfer to a non-distributable reserve account of the amounts required to fully pay up the new shares to be allocated;
- decide upon the capital increase or increases through the capitalization of reserves, additional paid-in capital or profits, corresponding to the issuance of the new shares allotted free of charge;
- carry out the acquisitions of the shares required under the share buyback program and allocate them to the allocation plan;
- determine the impact on the beneficiaries' rights of transactions altering the share capital or likely to affect the value of the shares to be allocated and carried out during the vesting period;
- take all appropriate measures to ensure compliance with any holding obligation, where applicable, imposed on the beneficiaries;
- and, more generally, do all that is necessary, in accordance with applicable law, for the implementation of this authorization.

The validity of this delegation is set at 18 months from the date of this Annual General Meeting.

This delegation, for the part not used, if applicable, supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 11, 2025, in its thirty-fifth resolution.

Thirty-sixth resolution – Authorization to be granted to the Board of Directors to grant stock options to employees and/or certain officers of the Company or related companies or economic interest groups

In order to attract and retain the high-quality executives and key employees, the Company wishes to be able to continue to allocate options for the subscription and/or purchase of shares.

It is proposed that you grant a delegation of authority to the Board of Directors for the purpose of granting options to subscribe for and/or purchase shares for the benefit of employees, certain of them, or certain categories of staff, and/or corporate officers as defined by law, both of the Company and of the companies or economic interest groupings affiliated with it under the conditions set out in Article L. 225-180 of the Commercial Code.

The total number of options that may be granted by the Board of Directors under this authorization may not grant entitlement to subscribe to or purchase more than 9.5% of the share capital on the date of the allocation decision, it being specified that it may not exceed the maximum percentage provided for by the regulations in force on the date of the grant decision and that this limit shall count against the overall nominal amount of shares that may be granted as provided for in the thirty-fifth resolution. To this amount will be added, as necessary, the par value of any capital increase necessary to preserve the rights of the beneficiaries of the options in the event of transactions involving the Company's capital, pursuant to the law and, if applicable, any contractual stipulations providing for other forms of preservation.

The subscription and/or acquisition price of the shares to be paid by the beneficiaries will be set on the day the options are granted by the Board of Directors in accordance with the regulations in effect and must not be less than the average opening price of the shares for the twenty trading days prior to the grant decision.

The term of the options determined by the Board may not exceed a period of 10 years from the grant date.

Thus, within the limits set forth above, the Board would have all power to set the other terms and conditions for the granting of options and their exercise and, in particular, to determine the conditions under which the options will be granted and to draft the list or categories of beneficiaries as scheduled above, to set the period or periods during which the options so granted may be exercised, to carry out or cause to be carried out all acts and formalities required in order to render final the capital increase or increases which may, where applicable, be implemented, to amend the Company's bylaws accordingly and, more generally, to do all that will be necessary.

The validity of this delegation is set at 18 months from the date of this Annual General Meeting.

This delegation supersedes, as from the date hereof, the unused portion, if any, of the delegation of authority granted by the General Meeting of June 11, 2025, in its thirty-sixth resolution.

THIRTY-SEVENTH RESOLUTION

Overall limit on the maximum authorized amounts set under the resolutions thirty-fifth and thirty-sixth

You are requested to set the maximum number of shares that may be issued under the thirty-fifth and thirty-sixth resolutions at 9.5% of the share capital outstanding on the date the shares or the options are granted. To this limit will be added, if applicable, the par value of any capital increase required to preserve, in accordance with the law and, if applicable, any contractual stipulations providing for other adjustments, the rights of the holders of rights or transferable securities giving access to the Company's capital.

The Board of Directors believe that this amount achieves an appropriate balance between safeguarding the interests of our existing shareholders and providing the Company with the financial flexibility required to implement an employee incentive plan, consistent with incentive practices at comparable U.S. companies.

THIRTY-EIGHTH RESOLUTION

Ratification of the amendment to Article 18 and Article 21 of the Company's bylaws

Pursuant to Article L.225-36 of the French Commercial Code, the Board of Directors decided to amend Articles 18 and 21 of the Company's bylaws at its meeting held on March 26, 2026, in order to align them with the new legislative provisions in force (Decree No. 2026-94 of February 13, 2026).

Article 18 of the Company's bylaws shall henceforth read as follows:

Previous wording	New wording
<p>[...] The notice of meeting must <u>also</u> specify the conditions under which shareholders may vote by post, and the <u>place where, and terms and</u> conditions according to which they may obtain postal vote forms.</p> <p>The notice of meeting may be sent, where applicable, with a proxy form and a postal voting form, under the conditions specified in Article 21 of these Articles of Association, or with a postal voting form only, under the conditions specified in Article 21 of these Articles of Association.</p> <p>[...]</p>	<p>[Unchanged] The notice of meeting must specify the conditions under which shareholders may vote by post, and the conditions according to which they may obtain postal vote forms.</p> <p>Paragraph removed</p> <p>[Unchanged]</p>

Article 21 of the Company's bylaws shall henceforth read as follows:

Previous wording	New wording
<p><i>If the Board of Directors decides at the time of convening the meeting to allow the transmission of voting or proxy forms by electronic means, the electronic signature of these forms may result from a reliable process for identifying the shareholder, guaranteeing its link with the remote form to which its signature is attached. The vote thus expressed before the meeting by this electronic means, as well as the acknowledgement of receipt given, will be considered as non-revocable writings and opposable to all. The proxy is however revocable in the same way as those required for the appointment of the proxy. In the event of a transfer of ownership of securities occurring before midnight (Paris time) on the second business day preceding the meeting, the Company will invalidate or modify accordingly, as the case may be, the proxy or the vote cast before the meeting by this electronic means.</i></p>	<p><i>If the Board of Directors decides at the time of convening the meeting to allow the transmission of voting or proxy forms by electronic means, the electronic signature of these forms may result from a reliable process for identifying the shareholder, guaranteeing its link with the remote form to which its signature is attached. The vote thus expressed before the meeting by this electronic means, as well as the acknowledgement of receipt given, will be considered as non-revocable writings and opposable to all. The proxy is however revocable in the same way as those required for the appointment of the proxy. In the event of a transfer of ownership of securities occurring before midnight (Paris time) on the fifth business day preceding the meeting, the Company will invalidate or modify accordingly, as the case may be, the proxy or the vote cast before the meeting by this electronic means.</i></p>

You are requested to ratify these amendments to the bylaws decided by the Board of Directors.

THIRTY-NINTH RESOLUTION

Amendment to Article 15 of the Company's bylaws to set the age limit for the Chief Executive Officer at 70 years

The Board proposes that the shareholders amend article 15 of the bylaws to set the age limit for the Chief Executive Officer at 70 years.

This amendment would enable Mr. Daniel Tassé to continue to exercise the duties of Chief Executive Officer.

A final paragraph would be added to Article 15 of the Company's bylaws, drafted as follows:

"No person aged 70 or over may be appointed as Chief Executive Officer. When this age limit is reached during the term of office, the duties of the Chief Executive Officer shall automatically cease at the end of the Ordinary General Meeting of Shareholders convened to approve the financial statements for the financial year in which the Chief Executive Officer reaches the age limit."

Of an ordinary nature:

FORTIETH RESOLUTION

Powers for formalities

Lastly, you are requested to grant all powers to the bearer of an original, a copy or an excerpt of the minutes of the Annual General Meeting to carry out all mandatory formalities with respect to registration and publication.

The Board of Directors invites you to cast your vote in favor of these resolutions .

THE BOARD OF DIRECTORS

5. PROCEDURES FOR PARTICIPATING IN THE ANNUAL GENERAL MEETING

A- Prior formalities to be completed in order to participate in the Annual General Meeting

Every shareholder, regardless of the number of ordinary shares held, has the right to participate in the Annual General Meeting under the conditions and in accordance with the procedures laid down by the laws and regulations in force.

Pursuant to Article R. 22-10-28 of the French Commercial Code, shareholders shall be required to provide evidence of their share registration in a securities account, in their name or in the name of the intermediary duly registered on their behalf (hereinafter the “account-holder institution”), on the fifth (5th) business day preceding the Annual General Meeting, i.e. on **Wednesday, May 27, 2026 at zero hour, Paris time** (hereinafter “D-5”):

- either in registered share accounts held by the Company’s account-holder institution: registration in an account under the above-mentioned conditions shall be sufficient;
- or in bearer share accounts held by the account-holder institution pursuant to Article L. 211-3 of the French Monetary and Financial Code: the registration in an account of the shares must be evidenced by a certificate of participation in the name of the shareholder issued by the account-holder institution.

The shareholder may at any time transfer all or part of his/her shares:

- if the transfer were to occur before D-5, the admission card, the vote cast prior to the Annual General Meeting or the proxy granted by the transferor would be invalidated or amended accordingly;
- if the transfer were to occur after D-5, the admission card, the vote cast prior to the Annual General Meeting or the proxy granted by the transferor would continue to be taken into account by the Company.

B- Procedures for participation in the Annual General Meeting

Every shareholder is entitled to participate in the Annual General Meeting:

- either by attending in person,
- or by being represented by the Chairman of the Annual General Meeting or any other natural person or legal entity of their choice,
- or by voting by post or electronically.

Any shareholder who has already cast a vote, sent a proxy or requested an admission card (under the conditions set out in Article R. 22-10-28 III of the French Commercial Code), by post or electronically, may no longer choose another form of participation in the Annual General Meeting.

1-1 Shareholders wishing to participate in person in the Annual General Meeting

1-1-1 Application for an admission card by postal mail:

The registered shareholder, entered in the register for at least one month as of the date of the meeting notice, shall receive by postal mail the meeting notice accompanied by a voting form, unless the shareholder has requested to be convened by electronic means. The shareholder may obtain an admission card by sending the voting form, duly completed, dated and signed, to Société Générale Securities Services – Service Assemblées – CS 30812 – 44308 Nantes Cedex 3, using the prepaid envelope enclosed with the notice of meeting.

If the shareholder has not received the admission card before the Annual General Meeting, the shareholder may go directly to the desk of the Annual General Meeting provided for this purpose, bearing an identity document.

The bearer shareholder who intends to participate in the Annual General Meeting must contact the account-holder institution with which his/her securities account is held in order to obtain an admission card. In such case, the account-holder institution shall issue a certificate of participation and shall transmit it directly to Société Générale Securities Services – Service Assemblées – CS 30812 – 44308 Nantes Cedex 3 for the purpose of issuing an admission card.

If the shareholder has not received the admission card prior to the Annual General Meeting, they must request the institution with which their account-holder is held to issue a certificate of participation, which will enable the shareholder to evidence their capacity as shareholder on D-5 in order to be admitted to the Annual General Meeting.

1-1-2 Request for an admission card by electronic means:

The shareholders may access the dedicated and secure Sharinbox and VOTACCESS websites from **Wednesday, May 13, 2026 at 9:00 a.m., Paris time**, until **Tuesday, June 2, 2026 at 3:00 p.m., Paris time**, the last business day before the date of the Annual General Meeting.

It is recommended not to wait until the last days to access the websites, in order to avoid any potential congestion.

The registered shareholder may submit an application for an admission card online on the secure VOTACCESS platform accessible via the website <https://sharinbox.societegenerale.com>:

- if logging in for the first time: by using the Sharinbox access code sent by post by Société Générale Securities Services or, failing that, by clicking on “Forgotten code?”; and the password likewise sent by post or, failing that, by clicking on “Forgotten password?”;
- if the shareholder has previously activated the “Sharinbox by SG Markets” account-holder: by using the login email address and the associated password or, failing that, by clicking on “Forgotten password?”.

Once logged in, **the registered shareholder** shall follow the on-screen instructions in order to request their admission card.

If he has not received his admission card before the Annual General Meeting, he may appear directly at the Annual General Meeting desk provided for this purpose, bearing an identity document.

The bearer shareholder may submit an online request for an admission card, provided that their **account-holder** institution has subscribed to VOTACCESS. In such a case, the bearer shareholder may

log in with their usual credentials to the Internet portal of their account-holder institution and then click on the icon corresponding to their DBV Technologies shares in order to access the VOTACCESS website.

Once logged in, **the bearer shareholder** shall follow the on-screen instructions in order to request their admission card.

If he has not received his admission card before the Annual General Meeting, he shall request his account-holder institution to issue to him a certificate of participation which will enable him to evidence his status as a shareholder at D-5 in order to be admitted to the Annual General Meeting.

1-2. Shareholders wishing to vote remotely or by proxy

Any shareholder who is unable to attend the Annual General Meeting in person may vote as follows:

- remotely, by postal or electronic means; or
- by proxy, by granting authority to the Chair of the Annual General Meeting or to a proxy of his choosing, by postal or electronic means. It is hereby recalled that, in the absence of any designation of a proxy on the voting form, the Chair of the Annual General Meeting shall cast a vote in favor of the adoption of the draft resolutions submitted or approved by the Board of Directors and a vote against the adoption of all other draft resolutions.

In all cases, the shareholder must imperatively:

- either complete, date and sign the voting form and return it by postal mail to Société Générale Securities Services – Service Assemblées – CS 30812 – 44308 Nantes Cedex 3 (see instructions below);
- or log on to the dedicated and secure websites and follow the prescribed procedure (see instructions below).

1-2-1 Postal remote voting or voting by proxy:

The registered shareholder, who has been recorded in the register for at least one month as at the date of the notice of meeting, shall receive by postal mail the notice of meeting together with a voting form, unless the shareholder has requested to be convened by electronic means. The shareholder shall return this voting form, duly completed, dated and signed, to Société Générale, either using the prepaid envelope enclosed with the meeting notice sent by postal mail, or by ordinary mail, to: Société Générale Securities Services - Service des Assemblées – CS 30812 - 44308 Nantes Cedex 3.

The bearer shareholder may request his **account-holder** institution with a view to obtaining the voting form. He must return said voting form, duly completed, dated and signed, to his account-holder institution, which shall be responsible for forwarding it, together with a certificate of participation issued by it, to Société Générale Securities Services - Service des Assemblées – CS 30812 - 44308 Nantes Cedex 3.

The shareholders may also obtain a voting form on the Company's website (www.dbv-technologies.com) or request in writing from Société Générale Securities Services - Service des Assemblées – CS 30812 - 44308 Nantes Cedex 3 that a voting form be sent to them by postal mail. In the latter case, only requests received no later than six (6) days prior to the date of the Annual General Meeting, i.e. on **Thursday, May 28, 2026**,

In order to be taken into account, the voting form must be received by the Assemblies Department of Société Générale Securities Services, in accordance with the procedures set out above, no later than three calendar days prior to the date of the Annual General Meeting, i.e. on **Sunday, May 31, 2026**, failing which it cannot be taken into account.

Under no circumstances must the voting forms be returned to the Company's postal address.

It is hereby recalled that in order to grant a proxy to a third party, the shareholder must complete and sign the voting form, indicating his or her surname, first name and address, as well as those of the proxyholder.

If he/she wishes to revoke the proxy holder appointed by postal means, the shareholder must request Société Générale Securities Services (if he/she is a registered shareholder) or his/her account-holder institution (if he/she is a bearer shareholder) to send him/her a new voting form bearing the wording "Change of proxy holder", and must return it in such a manner that Société Générale Securities Services is able to receive it no later than three (3) calendar days prior to the date of the Annual General Meeting, i.e. on **Sunday, May 31, 2026**.

1-2-2 Remote voting or voting by proxy by electronic means:

Shareholders also have the option of transmitting their voting instructions or appointing or revoking a proxy holder via the Internet prior to the Annual General Meeting, on the secure VOTACCESS platform, under the conditions set out below.

The VOTACCESS platform will be open from **Wednesday, May 13, 2026 at 9:00 a.m., Paris time**, to **Tuesday June 2, 2026 at 3:00 p.m., Paris time**.

It is recommended that shareholders should not wait until the final days to access the websites, in order to avoid any potential congestion.

The registered shareholder may cast his/her vote, or appoint or revoke a proxy online via the secure VOTACCESS platform, accessible via the website <https://sharinbox.societegenerale.com> in accordance with the procedures set out above. Once logged in, the registered shareholder must click on "Reply" in the "General Meetings" section of the home page, then on "Participate" in order to access the voting website. The shareholder must then follow the instructions displayed on the screen.

The bearer shareholder may vote, or appoint or revoke a proxy online, provided that the account-holder institution has subscribed to VOTACCESS. In such a case, the bearer shareholder may log in with the credentials customarily used on the Internet portal of the **account-holder** institution and then click on the icon corresponding to his DBV Technologies shares in order to access the VOTACCESS website. The shareholder shall then follow the instructions displayed on the screen.

If the account-holder institution does not offer access to the VOTACCESS platform, it is specified that notification of the appointment and revocation of a proxy may be effected by electronic means in accordance with the provisions of Article R. 22-10-24 of the French Commercial Code, by sending an email to the following electronic address: service.assemblee-generale@sgss.socgen.com.

This email must include, as an attachment, a scanned copy of the voting form specifying the shareholder's full name, first name, address and bank details, as well as the name, first name and address of the proxy appointed or revoked, together with the certificate of shareholding issued by the account-holder institution.

Furthermore, **the bearer shareholder** shall be required to request its account-holder institution to send written confirmation to Société Générale Securities Services, at the above-mentioned address.

Only notices relating to the appointment or revocation of a proxy may be sent to the above-referenced email address; any other request or notice concerning a different subject matter may not be taken into consideration and/or processed.

In order for the appointments or revocations of proxies expressed by electronic means to be taken into consideration, the confirmations must be received by Société Générale Securities Services no later than **Tuesday June 2, 2026 at 3:00 p.m. (Paris time)**.

C- Written questions

From the date on which the documents submitted to the Annual General Meeting are published on the Company's website and until the fourth (4th) business day preceding the date of the Annual General Meeting, i.e., on **Thursday, May 28, 2026**, any shareholder may address written questions to the Chair of the Company's Board of Directors, in accordance with the provisions of Article R. 225-84 of the French Commercial Code. Such written questions must be sent by registered letter with request for acknowledgement of receipt addressed to the registered office, either at 107, avenue de la République, 92320 Châtillon, France, or by e-mail to the following address: investors@dbv-technologies.com. They must be accompanied by a certificate of registration in the share account.

D- Shareholders' right to information

The documents that must be made available to the shareholders in connection with the Annual General Meeting shall be so made available under the conditions provided for by the legal and regulatory provisions in force.

The documents and information referred to in Article R. 22-10-23 of the French Commercial Code (in particular the text of the proposed resolutions and the reports that will be presented to the Annual General Meeting) shall be posted online on the Company's website (www.dbv-technologies.com) no later than as from **Wednesday May 13, 2026**.

Pursuant to the provisions of Article R. 225-88 of the French Commercial Code, the documents and information referred to in Articles R. 225-81 and R. 225-83 of the French Commercial Code shall be posted online on the Company's website, and the Company shall thereby be exempted from sending them to the shareholders.

The Board of Directors

6. DOCUMENTS AND INFORMATION RELATING TO THE ANNUAL GENERAL MEETING

All documents and information referred to in Articles R. 225-81 and R. 225-83 of the French Commercial Code relating to the Annual General Meeting may be consulted and downloaded from the Company's website at the following address: www.dbv-technologies.com or by scanning the below QR Code.



Pursuant to the provisions of Article R. 225-88 of the French Commercial Code as amended by Decree No. 2026-94 of February 13, 2026, these documents are no longer sent to shareholders by postal mail.

7. CHANGES IN THE TERMS AND CONDITIONS GOVERNING THE MEETING NOTICE FOR REGISTERED SHAREHOLDERS AS FROM JULY 1st, 2026

This Annual General Meeting will be the last for which a meeting notice is sent by postal mail to registered shareholders.

Moving forward, DBV Technologies will convene its registered shareholders by email, without their prior consent being required, as is now provided for by Article R. 225-63 of the French Commercial Code, as amended by Decree No. 2026-94 of February 13, 2026, applicable as from July 1st, 2026.

Consequently, registered shareholders shall be required to consult their email inbox in order to consult their electronic meeting notice to forthcoming general meetings.